Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
03/2011 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions March listing by industry category 03/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
03/31/2011 > patent applications in patent subcategories. listing by industry category

20110077189 - Composition for stimulating natural killer cell activity: The present invention relates to a nutritional composition comprising dietary fibre for stimulating natural killer cell activity, in particular in patients infected with HIV, oncology patients and elderly.... Agent: N.v. Nutricia

20110077190 - Selective caspase inhibitors and uses thereof: The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I,... Agent:

20110077191 - Novel inhibitors of mammalian tight junction opening: The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. peptide tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition... Agent: Alba Therapeutics Corporation

20110077192 - Novel antibacterial peptides: The present invention relates to monomeric and multimeric peptidic compounds which have antimicrobial activity, particularly against Gram-positive and Gram-negative bacteria. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, for use as a disinfectant and/or detergent or for use as a preservative.... Agent: Spiderbiotech S.r.l.

20110077193 - Artemisinin derivatives with natural amino acids, peptides, and amino sugars for the treatment of infection and topical condition in mammals: The present invention discloses certain derivatives of artemisinin and the active principles contained in Artemisia annua extracts with amino acids, peptides, and amino sugars, and isomers and salts thereof (formula I). The compounds of the present invention possess wide-spectrum antibacterial and antifungal biological activity suitable for topical or oral application... Agent: Bioderm Research

20110077194 - Method for treating or preventing a functional vitamin b12 deficiency in an individual and to medical compositions for use in said method: A method and medical composition for the treatment and/or prevention of a functional Vitamin B12 deficiency in an individual that is brought about as a consequence of oxidative stress on biochemical pathways. The functional Vitamin B12 deficiency may eventually present as dementia, other neuropsychiatric abnormality and/or vascular disease. The method... Agent:

20110077195 - Liquid preparation of physiologically active peptide: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a... Agent: Kenji Kangawa

20110077196 - Non-standard insulin analogues: An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide. A first amino acid at position B31 is selected from glutamate and aspartate, and... Agent: Case Western Reserve University

20110077197 - Novel insulin derivatives having an extremely delayed time-action profile: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is... Agent: Sanofi-aventis Deutschland Gmbh

20110077198 - Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition: The present invention relates to compositions and methods for preventing and treating a condition in a mammalian subject that include at least one inhibitor of double stranded RNA dependent protein kinase (PKR-I) prior to or concurrently with the treatment, wherein the treatment results to an inhibition of activation of dsRNA-dependent... Agent:

20110077199 - Growth hormone polypeptides and methods of making and using same: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.... Agent: Amunix, Inc.

20110077200 - Combination therapy using low-dose doxepin for the improvement of sleep: A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia.... Agent: Somaxon Pharmaceuticals, Inc.

20110077201 - High affinity vegf-receptor antagonists: A cell-based screen is reported can be used to identify specific receptor-binding compounds in a combinatorial library of peptoids (N-alkylglycine oligomers) displayed on beads. This strategy was applied to the isolation of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)-binding peptoids, which were optimized to create lead compounds with high affinity... Agent:

20110077202 - Targeted coagulation factors and method of using the same: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the... Agent: Bayer Healthcare LLC

20110077203 - Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use: Methods and compositions are provided that allow for high-level expression of a factor VIII polypeptide. More specifically, methods and compositions are provided comprising nucleic acid and amino acid sequences comprising a modified factor VIII that result in high-level expression of the polypeptide. The methods and compositions of the invention find... Agent: Expression Therapeutics, LLC

20110077204 - Agent for targeted drug delivery to cerebral neurons: The present invention relates to targeting agents of drugs, more specifically, to targeting agents that cause drugs to be incorporated into brain neurons. The present invention further relates to medicines comprising the targeting agents and drugs. The present invention also relates to a method for targeting drugs to brain neurons.... Agent: Kagoshima University

20110077205 - Production and use of antitumoral cyclodepsipeptides: e

20110077206 - Use of hnf4alpha for treatment of human malignant solid tumors through induction-differentiation therapy: Use of hepatocyte nuclear factor 4α (HNF4α) for the treatment of human malignant solid tumors through induction-differentiation therapy is provided.... Agent: Second Military Medical University

20110077207 - Method for treating inflammation: A method for treating down-regulating IL-19 or mda7 by administering the soluble IL-20RA/IL-20R heterodimeric receptor.... Agent: Zymogenetics, Inc.

20110077208 - Expression of secreted human alpha-fetoprotein in transgenic animals: The invention features a process of expressing secreted recombinant human alpha-fetoprotein (rHuAFP) in the milk or urine of transgenic mammals.... Agent: Merrimack Pharmaceuticals, Inc.

20110077209 - Protein or glycoprotein from haliotis midae and its use as an immunotherapy agent: Disclosed is a protein or glycoprotein obtainable from a crude extract of Haliotis midae, with a molecular weight of approx. 30 kDa and an isoelectric point of around 4.3-4.5, possessing passive cutaneous anaphylaxis-inhibiting activity.... Agent: Abc Co S.r.l.

20110077210 - Hdac regulation assays, compounds and therapeutic compositions: This invention relates to the field of assays for compounds that interact with the binding of a PTB-containing protein, i.e. APPL (Adaptor protein containing PH domain, PTB domain and Leucine zipper motif) with histone deacetylase, in particular HDAC1. Compounds identified using said assays are useful in inhibiting HDAC activity and... Agent:

20110077211 - Methods and compositions for treating luminal inflammatory disease: Compositions, articles, and methods for treating and imaging vulnerable plaque and other inflamed regions in a patient rely on delivery of a conversion electron emitting source (CEES) to a body location. The CEES may be delivered by coupling to a substance which preferentially binds to vulnerable plaque or other inflammatory... Agent: Clear Vascular, Inc.

20110077213 - Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same: Methods are provided for treating and/or preventing kidney stones, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a... Agent: Astrazeneca Uk Limited

20110077214 - Method for treating hyponatremia employing an sglt2 inhibitor and composition containing same: Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are... Agent: Astrazeneca Uk Limited

20110077212 - Therapeutic uses of sglt2 inhibitors: Provided are methods of using one or more SGLT2 inhibitors, independently or in combination, for treating edema or reducing fluid retention. The invention also provides methods of using one or more SGLT2 inhibitors for the preparation of a medicament for treating edema or fluid retention. Methods are also provided for... Agent: Theracos, Inc.

20110077284 - Dry powder compositions for rna influenza therapeutics: A dry powder formulation for delivery to a mammal by inhalation, the formulation comprising particles comprising a lipid, a carrier, and one or more double-stranded siRNA molecules or dicer-active precursors targeted to influenza virus A method for treating or preventing influenza in a mammal comprising administering a therapeutically-effective amount of... Agent: Marina Biotech, Inc.

20110077283 - Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases: The present invention relates to methods and assays for identifying agents capable of inhibiting the mutant huntingtin protein, inhibiting or reducing polyglutamine-induced protein aggregation, and/or altering huntingtin protein conformation, which inhibition is useful in the prevention, amelioration and/or treatment of neurodegenerative diseases, and protein aggregation diseases more generally. In particular,... Agent:

20110077286 - Oligonucleotide duplexes comprising dna-like and rna-like nucleotides and uses thereof: Novel oligonucleotide pairs which can form a duplex comprising one or more DNA-like nucleotides (e.g., 2′-substituted arabinonucleotides (ANA)); in combination with one or more RNA-like nucleotides (e.g., 2′-substituted ribonucleotides (RNA) and/or locked nucleic acid nucleotides (LNA)), are disclosed. The use of such oligonucleotide duplexes, such as for silencing the expression... Agent:

20110077285 - Rna antagonist compounds for the modulation of pik3ca expression: The invention relates to oligomeric compounds (oligomers), which target PIK3CA mRNA in a cell, leading to reduced expression of PIK3CA. Reduction of PIK3CA expression is beneficial for the treatment of certain medical disorders, such as hyperproliferative diseases (e.g., cancer). The invention provides therapeutic compositions that include the oligomers and methods... Agent: Santaris Pharma A/s

20110077289 - Method of treating pneumoconiosis with oligodeoxynucleotides: Methods are disclosed for treating, preventing or reducing the risk of developing occupational lung diseases, such as pneumoconiosis. In several embodiments, the methods include administering a therapeutically effective amount of the suppressive ODN to a subject having or at risk of developing a pneumoconiosis, thereby treating or inhibiting the pneumoconiosis.... Agent:

20110077287 - Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions: The present invention relates to a pharmaceutical composition containing an mRNA that is stabilised by sequence modifications in the translated region and is optimised for the translation. The pharmaceutical composition according to the invention is particularly suitable as an inoculating agent as well as a therapeutic agent for tissue regeneration.... Agent: Curevac Gmbh

20110077288 - Pharmaceutical compositions for treatment of microrna related diseases: The present invention provides compositions and methods of treatment of diseases that are sensitive to drugs that downregulate the function of microRNA's, mRNA, non-coding RNA, or viral genomes. In particular, it has been discovered that a very long term effect of an anti microRNA oligonucleotide may be obtained when administered... Agent: Santaris Pharma A/s

20110077215 - Dna methylation as a target for diagnosis and treatment of chronic lymphocytic leukema (cll): Global DNA methylation is a predictor of aggressive disease in patients with chronic lymphocytic leukemia. The higher the DNA methylation, the more likely a patient is going to require systemic therapy. Although there is a gradual decline in global DNA methylation with increasing age in normal individuals, the methylation index... Agent: The University Of Utah Research Foundation

20110077216 - Compositions and methods for the treatment of atherosclerosis and other related diseases: The present invention provides compositions and methods for the treatment of atherosclerosis and other related diseases. In some embodiments, a method comprises providing a composition and forming a coating of the composition on at least a portion of the interior and/or exterior surface of a tissue lumen or other body... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20110077219 - Ophthalmic pharmaceutical compositions based on amino acids and sodium hyaluronate: This invention relates to opthalmic wound-healing pharmaceutical compositions based on amino acids and sodium hyaluronate.... Agent: Solartium LLC

20110077217 - Selectively depolymerized galactomannan polysaccharide: Disclosed herein are compositions and methods for treating diseases such as cancer. The compositions comprise one or more polysaccharides in an admixture with one or more therapeutic agents. This admixture can be administered to a subject in need thereof using any known method of administration. The therapeutic agent, if administered... Agent: Pro-pharmaceuticals, Inc.

20110077218 - Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate: This invention relates to wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate.... Agent: Solartium LLC

20110077220 - 4-oxo,1-4-dihydroquinoline m1 receptor positive allosteric modulators: The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions... Agent:

20110077221 - Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof: This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle.... Agent:

20110077222 - Sustained-release opiate and opiate derivative compositions: The present invention provides sustained-release opiate compositions. In particular, the present invention provides sustained-release opiate compositions that include an opiate attached to a blood albumin binder. The present invention also relates to methods of administering an opiate with a sustained release pharmacokinetic profile.... Agent: Mallinckrodt Inc.

20110077223 - Chimeric promoters for use in plants: The present invention provides polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides expression constructs containing the polynucleotide molecules useful for expressing transgenes in plants. The present invention also provides transgenic plants and seeds containing the polynucleotide molecules useful for expressing transgenes in plants.... Agent:

20110077224 - Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes: Described herein are compositions of an linoleic phospholipid for inhibiting inflammatory pathways or neurodegenerative processes. Also provided are uses of such compositions and methods of inhibiting inflammatory or neurodegenerative processes by administering a composition that includes an linoleic phospholipid and optionally a carrier to a cell, cell culture or subject... Agent:

20110077225 - 4-substituted tetracyclines and methods of use thereof: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.... Agent: Paratek Pharmaceuticals, Inc.

20110077226 - Methods for inhibiting the development of huntington's disease: This invention relates to Huntington's disease and more specifically to methods for inhibiting the development of or treating Huntington's disease by administering estrogen, testosterone, precursors thereof or combinations thereof.... Agent:

20110077228 - Novel c-21-keto lupane derivatives preparation and use thereof: wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically... Agent:

20110077227 - Novel lupane derivatives: The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infections by administering therapeutically effective... Agent:

20110077229 - Steroid containing drug delivery systems: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.... Agent: Allergan, Inc.

20110077230 - Copper organocomplexes, use thereof as antitumor means and for protecting healthy tissue from ionizing radiation: The present invention relates to copper-organic complexes and pharmaceutical compositions containing the same. They can be used especially in the treatment of diseases caused by hyperproliferative cells and, in addition, protect healthy tissue from ionizing radiation. They are prepared by reacting a copper(II) acylate with an organic compound selected from... Agent: Charite - Universitatsmedizin Berlin

20110077231 - Compounds: Novel compounds, with the following being exemplary:... Agent: Boehringer Ingelheim International Gmbh

20110077232 - Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug: The present invention relates to compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic, in particular ezetimibe and fenofibrate. The invention discloses also their use as cholesterol-reducing drugs, as drugs having immunosuppressive properties, antioxidant, antithrombotic and anti-inflammatory activity, effects on endothelial function, and for treating and/or preventing acute coronary syndromes,... Agent: Nicox S.a.

20110077233 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Exelixis, Inc.

20110077234 - Urea glucokinase activators: e

20110077235 - Apoptosis signal-regulating kinase 1 inhibitors: The present invention relates to apoptosis signal-regulating kinase 1 (“ASK1”) inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using... Agent:

20110077236 - New carboxylic acid amides, the preparation thereof and their use as medicaments: e

20110077237 - Kinase inhibitors: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20110077238 - Methods and compositions for deterring abuse: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the... Agent: Acura Pharmaceuticals, Inc.

20110077239 - Glycine receptor agonists for the treatment of phantom phenomena: A medicament for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the production of such a medicament, and a method for the treatment of such phantom phenomena... Agent:

20110077240 - Inhibitors of protein tyrosine kinase activity: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions... Agent:

20110077242 - Diaminopyrimidines as p2x3 and p2x2/3 antagonists: i

20110077241 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6, and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control... Agent: Abbott Gmbh & Co. Kg

20110077243 - Triazolopyridine compounds useful as kinase inhibitors: A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.... Agent: Bristol-myers Squibb Company

20110077244 - Novel thiophenediamine derivative having urea structure: The present invention relates to synthetic studies of a novel thiophenediamine derivative having a urea structure and to finding pharmaceutical actions thereof. The present invention provides a compound represented by the following general formula (1) or a salt thereof. In the formula (1), R1 and R2 are the same or... Agent: Santen Pharmaceutical Co., Ltd.

20110077246 - Bicyclic heterocyclic compounds pharmaceutical compositions containing these compounds, their use and process for preparing the same: e

20110077245 - Substituted 2-alkyl quinazolinone derivatives as parp inhibitors:

20110077247 - Class of histone deacetylase inhibitors: wherein: Q is a bond, CH2, CH—NR3R4, NR5 or oxygen, X is CH or nitrogen, Y is a bond, CH2, oxygen or NR6, Z is CH or nitrogen, R1, R2 are, independently, hydrogen, halogen, C1-C6 alkyl or C1-C6 haloalkyl, R11, R12 are, independently, hydrogen or C1-C6 alkyl, and R3, R4,... Agent: Dac S.r.i.

20110077248 - Imidazopyridine and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20110077249 - 1,2,4-triazolylaminoaryl (heteroaryl) sulfonamide derivatives: o

20110077250 - Compounds for modulating rna binding proteins and uses therefor: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.... Agent:

20110077251 - Novel 17 beta lupane derivatives: wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the invention also relates to methods for prevention or treatment of HIV infection by administering therapeutically effective amounts of a compound of formula (I), or a pharmaceutically acceptable... Agent:

20110077252 - Pyridyl derivatives, their preparation and use: The present invention relates to pyridyl derivatives capable of inhibiting phosphatidylinositol-3-kinase (PI3k), mammalian target of rapamycin (mTOR) and/or hypoxia inducible factor 1α (HIF-1α) mediated signaling. Also disclosed are processes for preparation of the pyridyl derivatives, and their use in the manufacture of pharmaceutical compositions for the treatment of clinical conditions... Agent:

20110077253 - Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses: The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.... Agent: Abbott Gmbh & Co. Kg

20110077254 - Compounds: e

20110077255 - Substituted xanthine derivatives: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Concert Pharmaceuticals, Inc.

20110077256 - Mediators of hedgehog signaling pathways, compositions and uses related thereto: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function by contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize hedgehog activity.... Agent:

20110077257 - Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof: wherein p, n, A, B, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the... Agent: Sanofi-aventis

20110077258 - Treatment of malaria: The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.... Agent: La Jolla Bioengineering Institute

20110077259 - Compositions and methods for treating and preventing dermatoses: The invention encompasses protectant agents including uracil or a metabolite thereof that effectively prevent and/or treat the cutaneous toxicities and dermatological side-effects associated with chemotherapeutic agents. Additionally, and surprisingly compositions including uracil or a metabolite thereof are effective for treating or preventing various dermatoses.... Agent:

20110077260 - Methods, compositions, and kits for organ protection during systemic anticancer therapy: Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.... Agent:

20110077261 - Prevention of hiv-infection: This invention relates to the use of a parenteral formulation comprising the NNRTI TMC278 for the long term prevention of HIV infection in a subject at risk of being infected by HIV, which comprises the intermittent administration of the said formulation at long time intervals.... Agent:

20110077262 - Novel spirochromanone carboxylic acids: The invention relates to a compound of a general formula (I): wherein A represents a linking group; Ar1 represents a group formed from an aromatic ring; R1 and R2 each independently represent a hydrogen atom, a halogen atom, a cyano group, a C2-C6 alkenyl group, a C1-C6 alkoxy group, a... Agent:

20110077263 - Methods and compositions of toll-like receptor (tlr) agonists: There is provided a method of activating a Langerhans cell (LC) exposed to a human papillomavirus (HPV) to induce a HPV-specific immune response, by administering to a subject an effective amount of a toll-like receptor (TLR) agonist, thereby activating the LC exposed to the HPV to induce the HPV-specific immune... Agent: University Of Southern California

20110077264 - Derivatives of 5-pyridinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics: e

20110077266 - Diamine derivatives: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.... Agent: Daiichi Sankyo Company, Limited

20110077265 - Inhibitors of iap: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1... Agent: Genentech, Inc.

20110077268 - Kinase inhibitors and methods of use: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PB kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.... Agent:

20110077267 - Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability... Agent: Japan Tobacco Inc.

20110077269 - Derivatives for modulation of ion channels: Sulfonamide derivatives act as ion channel antagonists. The compositions are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Incorporated

20110077270 - Compositions and methods for treating ocular inflammation with lower risk of increased intraocular pressure: A composition for treating or controlling an ocular disease or condition comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), which disease or condition has an etiology, or results, in inflammation. The composition can optionally include an anti-inflammatory agent, an anti-infective agent, or both. The composition can be formulated for topical application,... Agent:

20110077271 - Process for the preparation of donepezil hydrochloride: The present invention provides a process for preparing donepezil or a salt thereof, the process comprising reducing a 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methylene]pyridonium halide of formula II, wherein X is bromide or chloride, in the presence of an ionic compound, a solvent, a catalyst and a source of hydrogen, to form donepezil and optionally... Agent: Cipla Limited

20110077272 - Pulmonary formulations of triptans: A pharmaceutical composition includes triptans, such as sumatriptan, and may be used in therapy. The composition may be administered via the inhaled route.... Agent: Vectura Limited

20110077273 - New benzimidazole derivatives: p

20110077274 - Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors: The compounds of Formula 1 can be incorporated in pharmaceutical compositions and used in methods of treatment of alpha 2 receptor mediated diseases and conditions.... Agent: Allergan, Inc.

20110077275 - Antioxidant compositions for soft oral tissue and methods of formulation and use thereof: One embodiment of the invention is directed to an oral antioxidant composition including between 0.0001% and 5.0% w/w antioxidant, wherein the antioxidant includes cinnamic acid derivative, tetrahydrocurcuminoids, or phloretin and an orally pharmaceutically acceptable carrier. The composition may have a pH of at least 5.0. According to still further embodiments,... Agent:

20110077276 - Methods and compositions for reduction of side effects of therapeutic treatments: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a... Agent:

20110077277 - Organic compounds: e

20110077278 - Antifungal compositions and methods: A combination product including a mixture of 3-iodpropynyl-N-n-butylcarbamate (“IPBC”) and 2-n-N-butyl-1,2-benzisothiazolin-3-one (“BBIT) for use as a fungicide and growth inhibitor in industrial applications. Combination products of the present invention are effective for inhibiting the growth of microorganisms, and exhibit a synergistic antifungal effect against fungi such as, for example, Aspergillus... Agent: Troy Corporation

20110077279 - Angiotensin ii receptor antagonists: c

20110077280 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV... Agent: Bristol-myers Squibb Company

20110077281 - Formulations comprising triptain compounds: i

20110077282 - Novel compounds from antrodia camphorata: Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions... Agent: Well Shine Biotechnology Development Co., Ltd.

20110077290 - Heterocyclic compounds and thrombopoietin receptor activators: wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X... Agent: Nissan Chemical Industries Limited

20110077291 - Preparations of taxanes for intravenous administration and the preparation method thereof: The present invention relates to the field of medical technology. More specifically, the present invention relates to a preparation of taxanes for intravenous administration, which consists of two parts: a drug solution and an emulsion. Said drug solution consists of paclitaxel or docetaxel, a pH regulator and a solvent for... Agent:

20110077292 - Forskolin carbonates and uses thereof: e

20110077293 - Gambogic amine, a selective trka agonist with neuroprotective activity: Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO2H) has been replaced by an amine group (CH2NR1R2). In some embodiments, the compounds selectively bind to TrkA but not TrkB or C, robustly... Agent: Emory University

20110077294 - R-(-) / s-(+)-7-[3-n substituted amino-2 hydroxypropoxy] flavones: The present invention provides an optically active compound of general formula (I) and salts thereof: wherein R′ is selected from a group consisting of t-butyl amine, n-butylamine, iso-butylamine, iso-propyl amine, 4-phenyl-piperazine-1-ylamine, 4-(2-methoxyphenyl)-piperazin-1-ylamine, and 3,4-dimethoxy phenethyl amine; wherein R1, R2 and R3 are selected from the group consisting of hydrogen, methyl... Agent:

20110077295 - Andrographolide derivatives and use thereof in manufacture of medicaments: The present invention relates to an andrographolide derivative of the formula (I), wherein R1, R2 and R3 are same or different substituents selected from hydrogen, substituted or unsubstituted organic acid radicals, inorganic acid radicals, alkyl, aryl or heteroaryl, and at least one of R1, R2 and R3 is R-lipoic acid,... Agent: Panorama Research Inc.

20110077296 - Method and composition for delivering zinc to the nasal membrane: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.... Agent: Zicam, LLC

20110077297 - Compositions and methods for treatment of inflammation and hyperkeratotic lesions: A method of treating inflammation and hyperkeratotic lesions in a mammal in need thereof, by administering the following compound (NVX-207), a related compound, or a pharmaceutically acceptable salt thereof to the mammal.... Agent: Novelix Pharmaceuticals, Inc.

20110077298 - Retinoid derivative and pharmaceutical composition and use thereof: The invention relates to a retinoid derivative and pharmaceutical composition and use thereof. The compound of the invention is capable of preventing or treating hematological tumours, such as acute leukemia, chronic leukemia, multiple myeloma and lymphoma, solid tumours, such as liver cancer, rectal cancer, mammary cancer and esophagus cancer, and... Agent: Anhui New Star Pharmaceutical Development Co., Ltd

20110077299 - Inhibitors of alpha4 mediated cell adhesion: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.... Agent:

20110077300 - Metabolic benefits to butyrate as a chronic diet supplement: Sodium butyrate was chronically administrated through diet supplementation at 5% w/w in a high fat diet. Supplementation of butyrate prevented development of insulin resistance and obesity in C57BL/6J mice on a high fat diet, and in mice fed on a regular diet of tributyrin. Fasting blood glucose, insulin, and insulin... Agent:

20110077301 - Novel methods of administering a mixture of fatty acids for the treatment of non-human mammals: Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration.... Agent: Ceva Sante Animale Sa

20110077302 - Enzymatic synthesis of sphingolipids: The invention relates to the enzymatic synthesis of sphingolipids and compositions that contain sphingolipids from lysosphingolipids and carbonic esters, and to cosmetic, dermatological or pharmaceutical formulations containing said sphingolipids or compositions.... Agent: Evonik Goldschmidt Gmbh

20110077303 - Increasing glutathione levels for therapy: The present invention concerns compositions and methods related to utilizing glycine and N-acetylcysteine for a variety of methods, including, for example, reducing deleterious effects of oxidative stress; treating and/or preventing diabetes; and/or increasing GSH levels.... Agent:

20110077304 - 1-aminocyclohexane derivatives for the treatment of cochlear tinnitus.: The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.... Agent: Merz Pharma Gmbh & Co., Kgaa

20110077305 - 5-lipoxygenase inhibitors: The use of compounds of the formula (I) Ar1-L1-Ar2-L2-C(R3)(R4)N(OR1)C(═Y)—R2 (I) where Y is selected from O or S; R1 is H, a salt or readily hydrolysable substituent; R2 is selected from H or CH3, CH2F, CF2H or CF3; R3 and R4 are selected independently from H, C 1-4 alkyl or... Agent:

20110077306 - Stat3 inhibiting compositions and methods: STA-21-related compounds, for example CLT-005, are shown to prevent dimerization of STAT3, thereby inhibiting STAT3 activity. Inhibition of STAT3 activity is shown to reduce intraocular inflammation and neovascularization, symptoms of eye-related diseases such as age-related macular degeneration. Inhibition of STAT3 prevents STAT3 from transcriptionally activating downstream gene targets that are... Agent: Charlesson, LLC

20110077307 - Astaxanthin-containing pet foods: There is provided pet food comprising astaxanthin and/or an ester thereof as an active component and having an effect of deodorizing excrement such as urine and feces, effects of improving sleep, sensibility such as perception and cognition, and visual sense, and an effect of treating, improving or preventing diabetes and... Agent: Fuji Chemical Industry Co., Ltd.

20110077308 - Agonists of bitter taste receptors and uses thereof: The present invention relates to agonists of the human bitter-taste receptor hTAS2R40 and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R40 bitter taste transduction or bitter taste response.... Agent: Deutsches Institut Fur Ernahrungsforschung Potsdam-rehbrucke Stiftung Des Offentlichen Rechts

20110077309 - Humectant composition: in which R is an alkylene group having 2 to 5 carbon atoms which may be substituted with at least one member selected from the group consisting of a methyl group and a hydroxyl group, and n is an integer of 1 to 3. The humectant composition of the present... Agent: Takasago International Corporation

20110077310 - Hydrophilic polyurethane coatings: The present invention relates to the use of specific polyurethane coatings, wherein the polyurethane urea is terminated by a copolymer unit of polyethylene oxide and polypropylene oxide.... Agent: Bayer Material Science Ag

  
03/24/2011 > patent applications in patent subcategories. listing by industry category

20110071071 - Psmb10: a diagnosis marker and therapeutic target of chronic rejection: The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one... Agent:

20110071072 - Antifungal bone cements: Antifungal bone cement compositions and methods of using the same are disclosed. In one aspect, a bone cement composition comprises an echinocandin lipopeptide antifungal agent and a cementing agent. Optionally, the echinocandin lipopeptide antifungal agent is selected from the group consisting of micafungin, caspofungin and anidulafungin. The echinocandin lipopeptide antifungal... Agent: Georgetown University, A Congressionally Chartered Institution Of Higher Education

20110071073 - Detection of mutations in a gene associated with resistance to viral infection, oas1: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the... Agent: Illumigen Biosciences, Inc.

20110071074 - Deuterated hepatitis c protease inhibitors: m

20110071075 - Promoter for bicarbonate secretion in gastrointestinal tract: A substance is described which can prevent or treat a disease associated with the secretion of an acid. A calcium receptor activator is the active ingredient in a composition which promotes bicarbonate secretion in a gastrointestinal tract. Examples of the calcium receptor activator include γ-Glu-X-Gly, wherein X represents an amino... Agent:

20110071076 - Novel exendin agonist compounds: Novel exendin agonist compounds are provided. These compounds are useful in treating Type I and II diabetes and conditions which would benefit by lower plasma glucose and delaying and/or slowing gastric emptying.... Agent: Amylin Pharmaceuticals, Inc.

20110071077 - Thrombopoietic compounds: The invention relates to the use of compounds, especially peptides or polypeptides, that have thrombopoietic activity, and pegylated forms thereof. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.... Agent: Amgen Inc.

20110071078 - Methods for treating neurological deficits: The present invention features methods and compositions for treating a patient who has a neurological deficit. The method can be carried out, for example, by contacting (in vivo or in culture) a neural progenitor cell of the patient's central nervous system (CNS) with a polypeptide that binds the epidermal growth... Agent:

20110071079 - Self-assembling poly(diol citrates)-protein hydrogels: The present invention can be directed to poly(diol-citrate)-based copolymers, compositions thereof comprising protein components and methods of use and assembly.... Agent:

20110071080 - Methods and compositions for sleep disorders and other disorders: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or... Agent:

20110071081 - Methods useful in the treatment of bone resorption diseases: The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a... Agent: Nps Pharmaceuticals, Inc.

20110071082 - Long lasting anti-angiogenic peptides: Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide... Agent: Conjuchem Biotechnologies Inc.

20110071083 - Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells: A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular... Agent: Nederlandse Organisatie Voor Toegepast-natuurwentenschappelijk Onderzoek Tnp

20110071084 - Benzazepine derivatives useful as vasopressin antagonists: wherein R1 represents a —CO—(CH2)n—COR2 group (wherein n is an integer of 1 to 4, and R2 is (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl;... Agent:

20110071085 - Use of survivin to treat kidney failure: The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of... Agent: Life Sciences Research Partners Vzw

20110071086 - Compositions for tissue repair/regeneration: The invention provides compositions and methods for cardiac repair and/or regeneration of tissues such as myocardium.... Agent:

20110071087 - Polypeptides having modulatory effects on cells: The present invention relates to peptides and polypeptides having the sequence SAVTFAVCAL or variants thereof, capable of binding to Calcineurin and/or to NS5A-TP2 and to their use in therapy, as well as to nucleic acid sequences and vectors encoding these peptides and polypeptides, and to cells comprising said polypeptides, nucleic... Agent:

20110071088 - Method for treating neurological disorders: The present invention is based on the discovery that suppressing the activity of the Nogo receptor (NgR) alone does not result in extensive axon regeneration unless the intrinsic growth program of neurons is also activated. Accordingly, the present invention is directed to methods of stimulating axon regeneration using a combination... Agent: Childrens Medical Center Corporation

20110071089 - Peptide composition for cancer treatment by inhibiting trpv6 calcium channel activity: The invention includes an isolated peptide comprising all or part of the amino acid sequence: EGKLSSNDTE GGLCKEFLHP SKVDLPR (SEQ ID NO: 1), wherein the peptide inhibits calcium channel activity. The peptides of the invention are useful for preventing or treating cancer.... Agent: Soricimed Biopharma Inc.

20110071090 - Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.... Agent: Stable Solutions LLC

20110071091 - Injectable aqueous ophthalmic composition and method of use therefor: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in... Agent:

20110071092 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Yale University

20110071093 - Novel reagents: Oligomeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble, non-peptidic oligomer and a pharmaceutically active agent. The oligomeric reagents are useful for, among other things, forming oligomer active agent conjugates. Related methods, compositions, preparations, and so forth... Agent: Nektar Therapeutics

20110071094 - (d)-allose inducing programmed cell death in hormone refractory prostate cancer lines: The present disclosure relates allose inducing programmed cell death in hormone refractory prostate cancer cell lines. More particularly, the present disclosure relates to a D-allose inducing programmed cell death in hormone refractory prostate cancer cell line of DU145 in dose-dependent manner by repressing cell growth and inhibiting cell cycle as... Agent: Industry-academic Cooperation Foudation, Gyeongsang National University

20110071095 - Compositions and methods for increasing telomerase activity: The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as,... Agent: Geron Corporation

20110071096 - Macrolides having antibiotic activity: The present invention relates to a semi-synthetic macrolide having antimicrobial activity, in particular antibacterial activity; pharmaceutical compositions comprising the macrolide; and methods of using the macrolide to treat or prevent an infection.... Agent: Idexx Laboratories, Inc.

20110071097 - Cephalotaxus esters, methods of synthesis, and uses thereof: The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and... Agent: Sloan-kettering Institute For Cancer Research

20110071098 - Flurbiprofen and muscle relaxant gel combinations thereof: A topical pharmaceutical gel includes flurbiprofen or a pharmaceutically acceptable salt of flurbiprofen, thiocolchicoside or a pharmaceutically acceptable salt of thiocolchicoside, and menthol. Pharmaceutical combinations of flurbiprofen, thiocolchicoside, and menthol in the form of topical gels with anti-inflammatory, analgesic, and myorelaxant activities are described.... Agent: Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi

20110071099 - Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer: The present invention relates to cationic ceramides, their dihydro-analogs and aromatic analogs and their derivatives, comprising a pyridinium group. Also provided are methods for making cationic ceramides comprising a pyridinium group, and their use for treating or preventing diseases associated with cell overproliferation and sphingolipid signal transduction, such as cancer,... Agent:

20110071208 - Lipid encapsulated dicer-substrate interfering rna: The present invention provides novel, stable nucleic acid-lipid particles comprising one or more Dicer-substrate dsRNAs and/or small hairpin RNAs (shRNAs), methods of making the particles, and methods of delivering and/or administering the particles (e.g., for the treatment of a disease or disorder). In some embodiments, the nucleic acid-lipid particles of... Agent: Protiva Biotherapeutics, Inc.

20110071210 - Methods and compositions for the treatment of cancer or other diseases: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells... Agent: City Of Hope

20110071211 - Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes: The present invention relates to a promoter region of a microRNA, the use of a microRNA, in particular miR-21, and related elements for the diagnosis and for the manufacture of a medicament for the treatment and/or prevention of fibrosis and/or fibrosis related diseases. Additionally, the invention concerns antisense oligonucleotides against... Agent: Julius Maximilians-universit&#xc4 T W&#xdc Rzburg

20110071209 - Rnai modulation of the rho-a gene and uses thereof: The invention relates to compositions and methods for modulating the expression of the RhoA gene, and more particularly to the downregulation of RhoA by chemically modified oligonucleotides.... Agent: Alnylam Pharmaceuticals, Inc.

20110071213 - Card-domain containing polypeptides, encoding nucleic acids, and methods of use: The invention provides caspase recruitment domain (CARD)-containing polypeptides and functional fragments thereof, encoding nucleic acid molecules, and specific antibodies. Also provided are screening methods for identifying CARD-associated polypeptides (CAPs), and for identifying agents that alter the association of a CARD-containing polypeptide with itself or with a CAP. Further provided are... Agent: Sanford-burnham Medical Research Institute

20110071215 - Compositions and methods for diagnosis, prognosis and treatment of mesothelioma: Described herein are compositions and methods for the diagnosis and treatment of mesothelioma patients and the prognosis of mesothelioma patients after surgical operation. Specifically the invention relates to microRNA molecules associated with diagnosis, treatment and prognosis of mesothelioma, as well as various nucleic acid molecules relating thereto or derived therefrom.... Agent:

20110071214 - Methods and compositions for the treatment of cancer: The present invention provides compositions and methods for the treatment of cancer, and is predicated at least in part on the use of gene fusion regions as therapeutic targets. The fusion region target may be physically embodied at the level of DNA, RNA or protein. Typically the fusion region is... Agent:

20110071212 - P185neu-encoding dna and therapeutical uses thereof: Plasmids containing sequences encoding different fragments of p185neu oncoprotein, able to induce an immune response against tumours expressing oncogenes of the ErbB family, and pharmaceutical compositions thereof.... Agent: Indena S.p.a.

20110071100 - Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases: The subject of the invention provides a pharmaceutical composition comprising a sulfobetaine, a sulfobetaine for therapy, uses thereof and methods of treating cancer obesity, age related macular degeneration or neurodegenerative diseases comprising administering a composition comprising a sulfobetaine.... Agent: Tiltan Pharma Ltd.

20110071102 - Compositions and methods to treat recurrent medical conditions: The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction.... Agent:

20110071101 - Nucleoside phosphonate analogs: The invention is related to phosphorus substituted nucleoside compounds and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent:

20110071103 - Methods of treating hepatic encephalopathy: The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of... Agent: Salix Pharmaceuticals, Ltd.

20110071106 - Glycosaminoglycan oral use and compositions: The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising... Agent:

20110071104 - Methods for treating osteoarthritis: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more... Agent:

20110071105 - Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate: This invention relates to wound-healing pharmaceutical or cosmetic (anti-skin aging) compositions in the form of a cream based on amino acids and sodium hyaluronate.... Agent: Solartium LLC

20110071107 - Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome: Water-soluble cellulose derivatives are useful in methods of preventing or treating metabolic syndrome or a symptom or condition associated with the metabolic syndrome in an individual, and in particular for preventing or treating one or more of the symptoms a) hypertension, b) proinflammatory or inflammation state and c) prothrombotic state.... Agent:

20110071108 - Beta-cyclodextrin derivatives as antibacterial agents: The invention provides a new class of antibiotics to which pathogenic bacteria have not been exposed, and thus should not have developed resistance. This new class of antibiotics are derivatives of β-cyclodextrin (β-CD), which is a cyclic molecule comprising seven D-glucose units.... Agent: Pinnacle Pharmaceuticals, Inc.

20110071109 - Histone deacetylase inhibitors as therapeutic agents for lysosomal storage disorders: Embodiments herein relate to the field of lysosomal storage disorders, and, more specifically, to methods of treating lysosomal storage disorders such as Niemann-Pick type C disease, for instance with inhibitors of histone deacetylases, particularly inhibitors of class 1 histone deacetylases. In various embodiments, methods of treating Niemann-Pick type C disease... Agent: Cornell University

20110071110 - Water dispersible policosanol cyclodextrin complex and method of its production: Disclosed is a formulation of policosanol with natural cyclodextrins resulting in a water dispersible form of policosanol. The disclosed process provides an economical commercial method for making the policosanol complex. The complex is suitable for incorporation into oral dosage forms and also in functional foods. One aspect of the present... Agent: Bioactives, LLC

20110071111 - Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome: Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing complications in patients with diabetes and/or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and an oral antidiabetic agent for treating and/or... Agent:

20110071112 - Compositions and methods for preserving colors and patterns of plants: The present invention relates to a composition for preserving plants, which comprises 5 carbon alcohol, at least one alcohol selected from the group consisting of 3 carbon alcohol and 4 carbon alcohol, a thiourea and at least one acid selected from the group consisting of tartaric acid and boric acid.... Agent: National Tsing Hua University

20110071113 - Thiazole derivatives and use thereof: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Merck Serono Sa

20110071114 - Compositions and methods for treating bacterial infections using ceftaroline: The present invention relates to compositions comprising ceftaroline or a prodrug thereof (e.g., ceftaroline fosamil) and methods for treating bacterial infections, such as complicated skin and structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP) by administering ceftaroline or a prodrug thereof, (e.g., ceftaroline fosamil).... Agent: Forest Laboratories Holdings Ltd.

20110071115 - Pharmaceutically useful heterocycle-substituted lactams: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders.... Agent: Cylene Pharmaceuticals, Inc.

20110071116 - Antimicrobial n-halogenated amino acid salts: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to... Agent: Alcon Research, Ltd.

20110071117 - Combinations of antioxidants and anti-inflammatory drugs in the treatment of inflammatory bowel disease: Disclosed herein are compositions comprising 5-aminosalicylic acid (5-ASA), or a pharmaceutically acceptable salt thereof and an antioxidant, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating an inflammatory bowel disease in a subject, reducing cytokine gene expression in colonic tissue of a subject, and reducing myeloperoxide... Agent: The Board Of Regents Of The University Of Oklahoma

20110071118 - Methods of making compositions comprising lecithin oils and nsaids for protecting the gastointestinal tract and providing enhanced therapeuitc activity: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to... Agent: The Board Of Regents Of The University Of Texas System

20110071119 - Heat resistant delivery system: A heat resistant chewable composition for the oral delivery of dietary supplements and pharmaceutical compounds. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include a gummy candy made from a binding agent with thermo-irreversible characteristics. The active ingredient may include an... Agent: Hero Nutritionals, LLC

20110071120 - Solid state forms of tapentadol salts: Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(−)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt.... Agent: Actavis Group Ptc Ehf

20110071121 - Diagnosis and/or prognosis of renal dysfunction: The present invention relates to a method for diagnosing and/or prognosing renal dysfunction. The method comprises the steps of:—(a) determining the level of an anti-inflammatory cytokine present in a urine sample from a subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic... Agent:

20110071122 - System for use by compounding pharmacists cists to produce hormone replacement medicine customized for each customer: This invention provides a system for compounding a pharmaceutical product for hormone replacement therapy. The system has a set of concentrated reagent compositions, each containing one or more steroid hormones dissolved in one or more solvents. The needs of each consumer are ascertained, and a pharmaceutical product is compounded for... Agent:

20110071123 - Noninvasive method for measuring histamine from skin as an objective measurement of itch: A method for measuring of histamine in an epidermis comprising applying an adhesive article to an epithelium of a mammal; allowing for adherence of epithelial cells to the adhesive article; removing the adhesive article from the epithelium of the mammal; preparing the adhesive article using standard laboratory methods for extraction;... Agent:

20110071124 - Compounds that inhibit production of sappb and ab and uses thereof: The present invention relates to compounds with activity as inhibitors of sAPPβ and Aβ production, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease and pharmaceutical compositions containing such candidate compounds.... Agent: The Trustees Of Columbia University In The City Of New York

20110071128 - Novel imidazopyridines: wherein R1, R2, R3, R4, R5 and A are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of various diseases, including central nervous system disorders such as Alzheimer's disease,... Agent:

20110071129 - Spirodiamine-diaryl ketoxime derivative: [wherein R1 a and R1 b each are a hydrogen atom, etc.; R2 is a hydrogen atom, a C1-6 alkyl, etc.; Ar1 is a 6-membered aromatic carbocyclic group or a 6-membered aromatic nitrogen-containing heterocyclic group; Ar2 is a group to be formed by removing two hydrogen atoms from a 6-membered... Agent:

20110071127 - Compounds which modulate the cb2 receptor: h

20110071126 - Inhibitors of beta-secretase:

20110071125 - Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity: This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.... Agent:

20110071130 - 2-aminobenzimidazoles for treating neurodegenerative diseases: The invention relates to 2-aminobenzimidazoles useful in treating disorders that are mediated by A2a receptor function, including neurodegenerative diseases including Parkinson's disease and inflammation. The compounds have general formula I:... Agent: Pharmacopeia, Inc.

20110071133 - Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors: Bicyclic aryl substituted triazoles or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110071132 - Substituted oxindole derivatives, drugs containing said derivatives and the use thereof: The invention relates to novel oxindol derivative of general formula (I), wherein substituents R1, R2, A, B and Y are such as defined in a claim 1. Drugs containing said derivatives and the use thereof for preventing and/or treating vassopress- and/or oxytocin-dependent-diseases are also disclosed.... Agent: Abbott Gmbh & Co. Kg

20110071131 - Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands: e

20110071134 - 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:... Agent: Millennium Pharmaceuticals, Inc.

20110071135 - Method and composition for treating alzheimer-type dementia: There is described a method for increasing the maximal tolerated close and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an... Agent: Chase Pharmaceuticals Corporation

20110071136 - Novel tricyclic protein kinase modulators: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.... Agent: Cylene Pharmaceuticals, Inc

20110071138 - Pharmaceutical composition for the treatment of premature ejaculation: The present invention provides an oral pharmaceutical composition for the treatment of premature ejaculation, and the composition provides the effective and excellent treatment of premature ejaculation as well as reduced side effects like nausea, vomiting, drowsiness, sedation effect, awakening effect, and weight-loss etc.... Agent: Yuhan Corporation

20110071137 - Process for preparing sustained release tablets: The present invention relates to a novel process for preparing sustained release tablets containing medicinal compounds and the products prepared by said process. The present invention is directed to a method of preparing a sustained release pharmaceutical composition having a predetermined drug release profile, but which is deviated therefrom by... Agent: Nostrum Pharmaceuticals, Inc.

20110071139 - Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), any of the formulas I1-I26 Ia1-3-Ij1-3 or pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical... Agent: Vitae Pharmaceuticals, Inc.

20110071140 - Therapeutic pyrazoloquinoline urea derivatives: i

20110071141 - Pesticidial condensed-ring aryl compounds: Condensed-ring aryl compounds of formula (I) and use of the same as a agrochemical for controlling noxious organisms wherein (X)mQ, A, R1, (Y)n and the grouping —W1—W2—W3—W4— are as defined herein.... Agent: Bayer Cropscience Ag

20110071143 - Fused triazole amines as p2x7 modulators: n

20110071142 - Identification and use of small molecules to modulate transcription factor function and to treat transcription factor associated diseases: The present invention relates to methods of identifying small molecule candidate agents capable of modulating transcription factor function such that the function/expression of a target transcription factor and/or proteins downstream of this target protein comprises the screening of small molecule libraries using in silico high throughput docking for candidate small... Agent: Beth Israel Deaconess Medical Center

20110071144 - Quinazoline derivatives and pharmaceutical compositions containing them: wherein m is an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro, trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio, or —NR5R6 (wherein R5 and R6, which may be the same or different, each represents hydrogen or C1-3alkyl); R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro; R3 represents hydroxy,... Agent:

20110071146 - 17betahsd type 5 inhibitor: It was found that an N-sulfonylindole derivative, where the indole ring is substituted by a carboxy group, a carboxy-substituted lower alkyl group or a carboxy-substituted lower alkenyl group at its carbon atom, has potent selective inhibitory activity against 17βHSD type 5 and may become a therapeutic agent and/or preventive agent... Agent: Astellas Pharma Inc.

20110071145 - Raf modulators and methods of use: The present invention relates to compounds of the Formula I, wherein G, A, X1, X2, X3, Z, E, Y, and X are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit,... Agent: Exelixis, Inc.

20110071147 - 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides: Disclosed are novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides, and their pharmaceutically acceptable salts and esters, that are selective inhibitors of KDR and/or FGFR kinases. These compounds and their pharmaceutically acceptable salts are anti-proliferative agents useful in the treatment or control of solid tumors, in particular solid cancerous tumors of the breast, colon,... Agent:

20110071148 - Compounds as the estrogen related receptors modulators and the uses thereof: The compounds according to formula VIII, their pharmaceutically acceptable acid or base addition salts, and the uses thereof is disclosed. These compounds and their pharmaceutically acceptable acid or base addition salts can be used for the preparing a medicament for modulating estrogen related receptor (ERR), and treating metabolic diseases, such... Agent: Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences

20110071149 - Selective kinase inhibitors: e

20110071150 - Indole derivatives as crac modulators:

20110071151 - Abt-263 crystalline forms: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.... Agent: Abbott Laboratories

20110071152 - 5-membered heterocycle-based p38 kinase inhibitors: Provided are 5-membered heterocycle-based p38 kinase inhibitors. Further provided are pyrazole and imidazole-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or... Agent:

20110071153 - Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors: Compounds of the formula I, in which R1, R2, R3′, R3, R4 and D have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft

20110071154 - Pyrrolidin-3-ylmethyl-amine as orexin antagonists: m

20110071155 - Tricyclic nitrogen containing compounds and their use as antibacterials:

20110071156 - Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6, and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control... Agent: Abbott Gmbh & Co. Kg

20110071157 - Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.... Agent: North Texas Medical Associates

20110071158 - New compounds: m

20110071159 - 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament: 6- (4-Cyclopropylpiperazin-1-yl) -2′-methyl- [3, 4′]bipyridinyl and salts and hydrates thereof interact with the histamine H3 receptor are defined.... Agent: High Point Pharmaceuticals, LLC

20110071160 - 1,3-dihydro-2h-pyrrolo[3,2-b]pyridin-2-one derivatives, preparation thereof and therapeutic uses thereof: in which: X is an unsubstituted or substituted divalent (C1-C5)alkylene radical; R1 is an —NR8R9 group; or an unsubstituted or substituted piperidin-3-yl or piperidin-4-yl radical; R2 is a hydrogen atom, a halogen atom, an Alk group or an OAlk group; R3 is a hydrogen atom, a halogen atom, an Alk... Agent: Sanofi-aventis

20110071162 - Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof:

20110071161 - Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof:

20110071163 - Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders: The disclosure relates to a method of treating or preventing a condition in a subject associated with the activation of an opioid receptor in the periphery by administering an effective amount of 5-(2-methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide (Compound I). In particular, the disclosure relates to a method of treating or preventing opioid-induced constipation or... Agent: Adolor Corporation

20110071164 - Erg channel openers for the treatment of cardiac arrhythmias: This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.... Agent:

20110071165 - Aza- and polyazanthranyl amides and their use as medicaments: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.... Agent: Novartis Ag

20110071166 - Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine: a

20110071167 - Method of treatment of age-related macular degeneration (amd): The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals... Agent: Prana Biotechnology Limited

20110071168 - Nitric oxide donors for inducing neurogenesis: There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric... Agent:

20110071169 - Preparation of polymorphic form of lapatinib ditosylate: The present invention is directed to two novel polymorph form (Form A and Form B) of lapatinib ditosylate, wherein Form A is the hydrate ditosylate salt of lapatinib, and Form B is anhydrate ditosylate salt of lapatinib. The present invention is further directed to amorphous form of lapatinib ditosylate and... Agent: Mai De Ltd

20110071171 - 2h- pyrimido [2, 1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110071173 - Imidazoquinazoline derivatives as anagrelide analogues for the treatment of myeloprolific diseases and thrombotic diseases: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110071174 - Substituted quinazolines: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110071172 - Substituted quinazolines as blood platelet lowering agents: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110071170 - Tricyclic pyrazolopyrimidine derivatives: A pyrazolopyrimidine compound represented by formula (1) that inhibits the function of HSP90 as a chaperone protein and that has antitumor activity, a medicament comprising a compound represented by formula (1), a pharmaceutical composition comprising a compound represented by formula (1), and a method for treating cancer using a compound... Agent: Daiichi Sankyo Company, Limited

20110071175 - Indoles and their therapeutic use: Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO2— or *—SO2NR3— wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3... Agent:

20110071177 - Fungicidal active substance combination: Methods of controlling fungi with an active compound combination that includes trifloxystrobin and pyrimethanil.... Agent: Bayer Cropscience Ag

20110071176 - Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same: In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.... Agent: Amarin Pharma, Inc.

20110071179 - Macrocyclic inhibitors of jak:

20110071178 - Methods and compounds for modulating cannabinoid activity: Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.... Agent: Northeastern University

20110071180 - Sub-type selective amides of diazabicycloalkanes: The present invention relates to compounds of the following formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and... Agent: Targacept, Inc.

20110071181 - Effervescent oral opiate dosage forms and methods of administering opiates: Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa.... Agent: Cima Labs Inc.

20110071182 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Smithkline Beecham Corporation

20110071183 - Manufacture of lozenge product with radiofrequency: The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said... Agent:

20110071185 - Manufacture of tablet in a die utilizing powder blend containing water-containing material: The present invention features the present invention features a process for making a tablet by compacting a powder blend in a die platen to form a tablet shape, wherein the powder blend includes a pharmaceutically active agent and a water-containing material, and applying energy to the tablet shape for a... Agent:

20110071184 - Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder: The present invention features a process for making a tablet by (i) compacting a powder blend in a die to form a tablet shape, wherein the powder blend contains a pharmaceutically active agent and a meltable binder and (ii) applying radiofrequency energy to the tablet shape for a sufficient period... Agent:

20110071186 - Organic compounds: This invention is directed to ophthalmic compositions comprising an ascomycin for once-a-day administration.... Agent:

20110071187 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Targacept, Inc.

20110071188 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Targacept, Inc.

20110071189 - 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is... Agent: Targacept, Inc.

20110071190 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, n, R1, R2, R3, R6, R7, W, and A are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such... Agent: Theravance, Inc.

20110071191 - Insecticidal compounds: A compound of formula (I): wherein R1 is pyrid-4-yl optionally substituted by one to four substituents independently selected from halogen, C1-3 alkyl or C1-3 haloalkyl; R2 is hydrogen, halogen, C1-4 haloalkyl or C1-4 haloalkoxy; R3 is trifluoromethyl, difluoromethyl or difluoromethoxy and R4 is hydrogen, fluoro or chloro, or R3 is... Agent: Syngenta Crop Protection, Inc.

20110071192 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Cycloheteroalkenyl Compound”); compositions comprising an effective amount of a Cycloheteroalkenyl Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke,... Agent: Purdue Pharma L.p.

20110071193 - Spot-on pesticide composition: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation... Agent: Sergeant's Pet Care Products, Inc.

20110071194 - Chemical compounds 572: s

20110071195 - Novel alkene oxindole derivatives:

20110071196 - Compounds which selectively modulate the cb2 receptor:

20110071197 - Bis-aryl compounds for use as medicaments: There is provided compounds of formula I, wherein ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and... Agent:

20110071198 - Nicotinic acid receptor ligands: The present invention relates, in general, to nicotinic acid receptor ligands and, in particular, to ligands that have a relative efficacy for activating a G-protein-coupled receptor function (e.g., signaling) that is greater than their relative efficacy for stimulating β-arrestin function (e.g., recruitment and/or signaling). The invention further relates to the... Agent:

20110071199 - Thiophenyl sulfonamides for the treatment of alzheimer's disease: e

20110071200 - 3-amino-benzo [d] isothiazole dioxide derivatives and their use as pesticides: A compound of Formula (I) or Formula (II) where W is C—R3; X is C—R4; Y is C—R5; R1 and R6, independently of each other, is, for example, H, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl or C1-C6-alkyl-C(═O); R2 is H; and R3, R4 and R5, independently of each other, are, for example,... Agent: Syngenta Crop Protection, Inc.

20110071201 - Phenol-containing azole compositions for the protection of industrial materials: c

20110071202 - Anti-hepatitis c virus agents and anti-hiv agents: An anti-hepatitis C virus agent or anti-HIV agent comprising, as an active ingredient, a fullerene derivative which has a nitrogen atom forming a ring together with adjacent bonded carbon atom pairs constituting the carbon cluster skeleton of the fullerene or a quaternary amine salt thereof is provided.... Agent:

20110071203 - Transmucosal veterinary composition comprising detomidine: The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition... Agent: Orion Corporation

20110071204 - Percutaneous absorption preparation: e

20110071205 - Use of cyclic ketoenols against phytopathogenic bacteria: The present invention relates to the use of known cyclic ketoenols against phytopathogenic bacteria.... Agent: Bayer Cropscience Ag

20110071206 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20110071207 - Oligomer-aryloxy-substituted propanamine conjugates: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.... Agent: Nektar Therapeutics

20110071216 - Reconstitutable reverse thermal gelling polymers: Biodegradable and bioabsorbable block copolymers, which can be in the form of solid powder or powder wax compositions that can be easily reconstituted into an aqueous polymer solution and exhibit reverse thermal gellation properties upon exposure to elevated temperatures, are provided. Methods of making using these copolymers are also provided.... Agent: Protherics Salt Lake City, Inc.

20110071218 - Novel amino acid derivatives, method for preparing same, and therapeutic use thereof: The disclosure relates to novel compounds of the formula (I) R1NH—CH(R2)CH2—S—S—CH2—C(R3)(R4)—CONH—C(R5)(R6)—COOR7, in which R1 is a (acyloxy)alkyl carbamate-C(O)—O—C(R8)(R9)—OC(O)—R10 group; R2 is a hydrocarbon chain, a methylene radical substituted by a heterocycle, R4 is a hydrogen atom and R3 is a phenyl or benzyl radical, a heteroaryl, a methylene group substituted... Agent: Pharmaleads

20110071217 - Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes: A new process for the manufacture of iodinated xanthenes in high purity includes a cyclization step followed by an iodination step. No extraction, chromatographic or solvent concentration steps are required, and the intermediate as well as final compounds are isolated via filtration or similar means. The process requires a single... Agent: Provectus Pharmaceuticals, Inc.

20110071219 - Hemostatic effects of glucono-delta-lactone: Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states.... Agent: University Of Medicine And Dentistry Of New Jersey

20110071220 - Use of tetronic acid derivatives for fighting insects and red spider mites by watering on the ground, droplet application or immersion application: u

20110071221 - Method for treating conditions mediated by ppar using macelignan:

20110071222 - Potentiators of insulin secretion: The present invention relates to a recognition that an analog of αKG can increase glucose-induced insulin secretion in vitro and in vivo in animals, particularly in mammals, and more particularly in humans and in rodents. By employing the methods of the invention, insulin secretion can be increased.... Agent: Wisconsin Alumni Research Foundation

20110071223 - Body cosmetics for wetted skin: e

20110071224 - Novel gamma-secretase inhibitor: The present invention provides a compound of the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R1 represents a linear or branched alkyl group having 1 to 4 carbon atoms or a phenyl group; R2 represents a linear or branched alkyl group having 1 to 4 carbon atoms... Agent: Kabushiki Kaisha Yakult Honsha

20110071225 - Method for obtaining a sequoyitol-containing extract from genus nephrolepis and uses thereof: A method for obtaining a sequoyitol-containing extract from a plant of genus Nephrolepis, comprising extracting with a solvent, recovering the solvent to give an extractum, subjecting the extractum to two-phase extraction and column chromatography, collecting the fractions containing sequoyitol, concentrating, filtration and drying. The main active ingredient of the extract... Agent: Guangzhou Welman New Drug R&d Co., Ltd.

20110071226 - Emollient composition: The invention relates to an emollient composition for topical use that comprises a combination of glycerol, Vaseline and liquid paraffin as an active principle, in the form of an oil-in-water or water-in-oil emulsion. The invention also relates to: the use thereof for preparing a drug for treating dry skin conditions... Agent: Pierre Fabre Dermo-cosmetique

20110071227 - Rapidly wetting material containing hydrocolloid, method for the manufacture thereof and use thereof: The present invention relates to a method for the production of a quickly wettable material containing natural hydrocolloid in the form of a shaped body, in which a material containing natural hydrocolloid in the form of a shaped body is exposed to a plasma.... Agent: Gelita Ag

20110071228 - Insecticidal formulations with improved long-term effect on surfaces: The present invention relates to compositions for the control of pests, in particular insecticidal suspension concentrates and spray solutions made from them, to processes for their preparation, and to the use of such formulations for the sustained control of animal pests (arthropods) on a variety of surfaces. The present invention... Agent: Bayer Cropscience Ag

  
03/17/2011 > patent applications in patent subcategories. listing by industry category

20110065629 - Enteral nutrient: The present invention relates to an enteral nutrient for inflammatory bowel disease patients, including an active hexose correlated compound obtained by culturing mycelia of basidiomycetes. The enteral nutrient of the present invention is an enteral nutrient which is expected to exhibit an advantageous effect of AHCC on cancer patients and... Agent: Amino Up Chemical Co., Ltd.

20110065628 - Medication combinations for the treatment of alcoholism and drug addiction: The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone.... Agent: University Of Virginia Patent Foundation

20110065627 - Transdermal delivery of medicaments with combinations of cetylated fatty fatty ester penetrant complexes: This invention describes a topical delivery mechanism that contains a mixture of cetylated fatty esters that act as transdermal carriers of desired therapeutic molecules. The proposed cetyl fatty ester penetrant-complex (Base CFEP-complex) contains specific cetyl fatty esters, polar solvents, a carrier base (gel, cream, lotion, patch or stick gel), antioxidants... Agent: Cymbiotics Inc.

20110065630 - Use of a octreotide as a therapeutic agent: The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical... Agent:

20110065631 - Process for preparation of hiv protease inhibitors: A process for the synthesis of bisfuran intermediates of formula (0) useful for preparing antiviral HIV protease inhibitor compounds is hereby disclosed. Furthermore disclosed is a HIV protease inhibitor of formula (IV) as well as various intermediates thereof.... Agent: Gilead Sciences, Inc

20110065632 - Pharmaceutical compositions of somatostatin-dopamine conjugates: The present invention is directed to improvements in compositions containing a somatostatin-dopamine conjugate which retains both somatostatin and dopamine activity in vivo, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2 (SEQ ID... Agent:

20110065633 - Ester-based peptide prodrugs: Prodrug formulations of bioactive polypeptides are provided wherein the bioactive polypeptide has been modified by the linkage of a dipeptide to the bioactive polypeptide through an ester linkage. The prodrugs disclosed herein in some embodiments have extended half lives of at least 1.5 hours (e.g., at least 10 hours), and... Agent: Indiana University Research And Technology Corporation

20110065634 - Glucagon receptor antagonists, compositions, and methods for their use: The present invention relates to compounds of general formula (I), wherein ring A, ring B, R1, R2, R3, Z, and L1 are selected independently of each other and are as defined herein, to compositions comprising the compounds, and methods of using the compounds as glucagon receptor antagonists and for the... Agent:

20110065635 - Methods and compositions for modulating insulin regulation: The present invention provides a combination of compounds capable of modulating xenin activity and, insulin secretion and weight gain. The invention also provides methods for modulating GIP activity and insulin secretion in a subject, by modulating xenin activity in the subject.... Agent: The Washington University

20110065636 - Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3): The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.... Agent:

20110065637 - Method to reduce slosh energy absorption and its damaging effects through the reduction of inelastic collisions in an organism: A first embodiment can be a method to reduce SLOSH energy absorption within an organism by reducing the inelastic collisions. A fluid containing organism can utilize an embodiment of the method wherein one or more of reversibly increasing pressure within the organs or cells, reversibly increasing the volume within the... Agent:

20110065638 - Novel crustacean androgenic gland hormone: The present invention relates to a novel crustacean androgenic gland hormone. More specifically, the invention relates to an androgenic gland hormone derived from Penaeus monodon. The invention relates further to the use of the hormone to influence the sex ratio in prawn and shrimp cultures, and to set up monosex... Agent: Moana Belgium Nv

20110065639 - Compositions and methods for visualizing and eliminating cancer stem cells: The present invention relates generally to the field of cancer diagnosis and treatment, and more particularly to compositions and methods that may be useful for eliminating cancer cells with stem-like characteristics. The disclosed compositions and methods may also be useful for managing breast cancer, ovarian cancer, cervical cancer or endometrial... Agent:

20110065640 - Anti-invasive and anti-angiogenic compositions: A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as... Agent: Angstrom Pharmaceuticals, Inc.

20110065641 - Polypeptide and dna thereof useful as a neovascular marker: The expression of KIAA1036 is enhanced in ovarian cancer and large bowel cancer and KIAA1036 expresses in umbilical vein endothelial cell and inhibits DNA synthesis in the cells, cell migrating and lumen formation. Therefore KIAA1036 is useful as a marker for neovascularization, vascular disease, inflammatory disease, entoptic neovascular disease, reproductive... Agent: Shionogi & Co., Ltd.

20110065642 - Pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion: The present invention provides a pharmaceutical composition for the treatment of dry eye and/or corneal and conjunctival lesion which comprises a recombinant human serum albumin produced by a recombinant yeast obtained by transforming a yeast with a gene for human serum albumin. Further, the present invention provides a method for... Agent: R-tech Ueno, Ltd.

20110065643 - Clusterin pharmaceuticals and treatment methods using the same: Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry... Agent: University Of Southern California

20110065644 - Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use: The present invention provides siRNA nucleic acid molecules that inhibit PCSK9 or apolipoprotein B expression. Methods of using the nucleic acid molecules are also provided.... Agent: Intradigm Corporation

20110065645 - Compositions and methods for modulating neuron degeneration and neuron guidance: Methods for inhibiting degeneration of a neuron, methods of treating a neurodegenerative disease, methods for promoting degeneration of a neuron are provided, methods for modulating neuron cell guidance of a neuron, as well as compounds useful in the methods of the invention, such as a Wnt compound, a Fzd3 dephosphorylating... Agent: The Regents Of The University Of California

20110065647 - Novel peptides isolated from spider venom, and uses thereof: The presently described subject matter relates to isolated spider venom peptides, which are used as potent and selective ion channel blockers, and to a composition and methods for treatment of pain.... Agent: Biosearch (2007) Ltd.

20110065646 - Use of a homeoprotein of the bicoid family for preventing or treating retinal ganglionic neuron degeneration: The invention relates to the use of a homeoprotein of the bicoid family, in particular of the Otx family, for enhancing the survival of cultivated retinal ganglion neurones, and for preventing or treating ganglion neuron degeneration particularly occurring in glaucoma.... Agent:

20110065648 - Advantageous mu-opiate receptor peptide compounds: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their activity.... Agent:

20110065649 - Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation: A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).... Agent: Centre National De La Recherche Scientifique (cnrs)

20110065650 - Methods of inhibiting tumor cell proliferation: The invention provides methods for inhibiting tumor cell proliferation by inhibiting FoxM1B activity, expression, or nuclear localization in a tumor cell. The invention also provides methods for preventing tumor progression in an animal comprising inhibiting FoxM1B activity, expression, or nuclear localization. Furthermore, the invention provides methods for inhibiting tumor cell... Agent: The Board Of Trustees Of The University Of Illinois

20110065651 - Heterocyclic substituted piperazines with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting... Agent: Pharmacopeia Drug Discovery, Inc.

20110065652 - Melanocortin receptor-specific peptides for treatment of sexual dysfunction:

20110065654 - Compositions and methods for alzheimer's disease: The present invention concerns methods and compositions of use for treatment of Alzheimer's Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Aβ) protein or peptide. Anti-Aβ antibodies are selected and sequenced. In certain embodiments, synthetic Aβ binding peptides are... Agent: Primex Clinical Laboratories, Inc.

20110065653 - Tat-utrophin as a protein therapy for dystrophinopathies: Disclosed is a fusion protein including a full-length TAT-utrophin or an anti-dystrophinopathic fragment thereof, a method of treating dystrophinopathies (including Duchenne muscular dystrophy) using the fusion protein, a pharmaceutical composition for treating dystrophinopathies in mammals comprising the fusion protein, and nucleic acid constructs for expressing the fusion protein.... Agent:

20110065656 - Dopaminergic mimetics: A method is described for providing acute symptomatic relief to a subject with Parkinson's Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic... Agent: Btg International Limited

20110065655 - Therapeutic composition to treat lesions caused by herpes simplex virus: The present invention is generally directed toward therapeutic compositions for treating infections caused by Herpes Simplex Virus (“HSV”). The therapeutic compositions meet a long felt need in the art of providing a treatment for lesions that result from HSV that drastically reduce the duration of a cold sore when vesicles... Agent:

20110065658 - Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same: Methods are provided for treating hyperuricemia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with an inhibitor of uric acid synthesis. Additionally, pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate or an inhibitor of uric acid synthesis or a... Agent: Bristol-myers Squibb Company

20110065657 - Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases: Polyhydroxylated aromatic compounds, and compositions containing them, are useful for the treatment of amyloidosis, especially Alzheimer's disease, and for the treatment of diseases characterized by α-synuclein fibril formation, especially Lewy body disease and Parkinson's disease.... Agent:

20110065660 - Chemosensory receptor ligand-based therapies: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.... Agent: Elcelyx Therapeutics, Inc.

20110065659 - Protopanaxadiol-type ginsenoside compositions and uses thereof: Provided herein are ginsenoside compositions comprising at least 10% (w/w) of a protopanaxadiol type of ginsenoside suitable for administration to a subject. Also provided are methods using the ginsenoside compositions for reducing acetaldehyde concentrations, preventing or ameliorating a symptom of elevated acetaldehyde concentration, or reducing the risk of diseases or... Agent:

20110065661 - Pharmacoperones for correcting disease states involving protein misfolding: This application relates to methods of identifying pharmacoperone agents that can restore function to a misfolded protein, such as a misfolded protein that causes disease. Also disclosed are methods of using such pharmacoperone agents to treat a disease or disorder that results from the misfolded protein.... Agent: Oregon Health & Science University

20110065662 - Compounds, compositions, and methods for protecting brain health in neurodegenerative disorders: Aspects of the invention relate to compounds, extracts and compositions thereof, and methods of using of the same, to treat neurodegenerative disorders and/or improve brain health. In certain embodiments, said compounds are pomegranate flavonoids.... Agent: Amazentis Sa

20110065774 - Chemically modified oligonucleotides and uses thereof: This invention relates generally to chemically oligonucleotides (e.g., modified oligonucleotides) useful for augmenting activity of a target gene.... Agent: Alnylam Pharmaceuticals

20110065775 - Compounds and methods for modulating expression of sglt2: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are... Agent: Isis Pharmaceuticals, Inc.

20110065777 - Double-stranded rna (dsrna) and method of use for inhibiting expression of a fusion gene: Specific inhibition of expression of a fusion gene in mammals occurs using a short, double-stranded ribonucleic acid molecule (dsRNA). The dsRNA comprises two separate non-linked RNA strands, an 51 strand and a complementary strand. The strands are 20 to 23 nucleotides in length, and the 51 strand is complementary to... Agent:

20110065770 - Formulations comprising antisense nucleotides to connexins: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation... Agent:

20110065771 - Inflammatory bowel disease therapies: The invention relates to methods of treating inflammatory bowel disease in a subject. Methods of promoting intestinal barrier function as well as related compositions are also provided.... Agent:

20110065776 - Method for treating hepatitis c infection: The present invention relates to a method for treating hepatitis C virus (HCV) infection, comprising administrating a subject in need thereof with a therapeutically effective amount of an inhibitor against a serine/threonine kinase (AKT) and an activator thereof. A method for screening a candidate agent for treating hepatitis C infection... Agent:

20110065778 - Rna interference mediated inhibition of muscarinic colinergic receptor gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and... Agent: Merck Sharp & Dohme Corp.

20110065773 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v.

20110065772 - Treatment of rheumatoid arthritis: The present invention provides a method for treating or inhibiting rheumatoid arthritis in a subject, the method comprising administering to the subject a therapeutically effective amount of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or nuclear accumulation or activity of c-Jun protein.... Agent: New South Innovations Pty Limited

20110065779 - Aav vector compositions and methods for enhanced expression of immunoglobulins using the same: Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single... Agent: Biosante Pharmaceuticals, Inc.

20110065780 - Insulin resistance improving agent: The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering... Agent: Japan Science And Technology Agency

20110065663 - Anti-cancer combination therapy: The present invention relates to a combination of therapeutic agents comprising: (a) a cytosine-based anti-cancer drug and/or a purine-based anticancer drug and (b) a therapeutic agent selected from the group consisting of thymidine phosphorylase inhibitors, and antibiotics against Mollicutes bacteria. The present invention also relates to the simultaneous, separate or... Agent: Katholieke Universiteit Leuven, K.u. Leuven R&d

20110065664 - Kinase protein binding inhibitors: The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.... Agent: University Of Florida Research Foundation

20110065665 - Stabilization of vitamin b12: The invention relates to preparations comprising vitamin B12 and a butanol, and to the use of butanol for stabilizing vitamins.... Agent: Bayer Animal Health Gmbh

20110065666 - Method of producing a bran product: The present invention relates to a method of manufacturing a cereal bran product containing beta-glucan. According to the method, a plastic mass is formed from cereal bran by means of a thermo-mechanical treatment, and the mass is brought into contact with an enzyme that breaks up beta-glucan, with or without... Agent: Valtion Teknillinen Tutkimuskeskus

20110065669 - Oxazolobenzimidazole derivatives: The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also... Agent: Merck Sharp & Dohme Corp.

20110065667 - Phenylpyrazole derivatives: e

20110065668 - Phenylpyrazole derivatives:

20110065670 - Skin beautifier: A skin beautifier contains sphingomyelin, which is a phospholipid, as an effective ingredient. In addition, skin-beautifying food or feed contains sphingomyelin as an effective ingredient. The present invention provides a skin beautifier and skin-beautifying food or feed supplying effects on beauty, such as skin-moisturizing and protecting effects, skin-roughness-preventing and improving... Agent: Snow Brand Milk Products Co., Ltd.

20110065671 - Bicyclic heterocycle derivatives and use thereof as gpr119 modulators: The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.... Agent:

20110065672 - Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis: The present invention concerns conjugate compounds comprising a bisphosphonate covalently bonded to a prostatic acid phosphatase inhibitor and compositions comprising such conjugates. Methods for treating and inhibiting prostate cancer bone metastases, and determining whether a conjugate is useful for such treatment are also provided. In some instances, the bisphosphonate is... Agent: Lehigh University

20110065673 - Novel leukotriene receptor agonist: The object has been achieved by finding that a marine product such as a squid phospholipid extract or an Akiami paste shrimp phospholipid extract contains the antagonists of BLT and CysLT1, which are leukotriene receptors. Therefore, the present invention provides a dietary composition and a pharmaceutical composition for inhibiting the... Agent: Bizen Chemical Co., Ltd.

20110065674 - Methods and compositions for improving cognitive function: The invention relates to methods and compositions for improving cognitive function by using a combination of valproic acid and analogs and derivatives thereof (“valproate”) and an acetylcholinesterase inhibitor (AChEI). In particular, it relates to the use of a combination of a valproate and an AChEI in treating age-related cognitive impairment... Agent: The Johns Hopkins University

20110065675 - Azo dye related small molecule modulators of protein-protein interactions: Azo dyes and suramin-related small molecules are effective in inhibiting the CD40/CD154 protein-protein interaction, an important co-stimulatory interaction involved in the activation of immune responses mediated by T- and B-cells. The compounds were found to be active as indicated by their IC50 values both in a cell-free binding assay and... Agent: University Of Miami

20110065676 - Combination therapies comprising par1 antagonists with nar agonists: The present invention is directed to a pharmaceutical composition comprising an effective amount of at least one PAR1 antagonist, at least one NAR agonist, optionally, an effective amount of at least one cardiovascular agent, and, optionally, a pharmaceutically acceptable carrier. The present invention also provides for the use of theses... Agent: Schering Corporation

20110065677 - Methods of treating inflammation with compositions comprising lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity: A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to... Agent: The Board Of Regents Of The University Of Texas System

20110065678 - Isoxazolidine derivatives: Novel glucocorticosteroids that are derivatives of isoxazolidine are useful as anti-inflammatory and antiallergic compounds.... Agent: Chiesi Farmaceutici S.p.a.

20110065680 - Metal complexes: A method for synthesizing a complex having the formula: [L3MO3]″ wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from −2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or... Agent:

20110065679 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such... Agent: Aeolus Pharmaceuticals, Inc.

20110065681 - Amide compounds, compositions and uses thereof: where A, B, W, X′, L, R1, R3, R4b, and m′ are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and... Agent:

20110065682 - Heterocyclic compounds as factor ixa inhibitors: The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder.... Agent:

20110065683 - Trisubstituted pyrazoles as acetylcholine receptor modulators: e

20110065684 - Phthalazine derivatives as parp inhibitors:

20110065685 - Novel indoles are cannabinoid receptor ligands:

20110065686 - Chemical compounds having antiviral activity against dengue virus and other flaviviruses: Use of chemical compounds obtained in silico for the preparation of pharmaceutical compositions to attenuate or inhibit Dengue virus infection. Particularly, through the interference or the modulation of several stages of viral replication cycle related with the entry of virus into host cells and the assembly of mature progeny virions.... Agent:

20110065690 - Compositions and methods for treatment of leukemia: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.... Agent: University Of Virginia Patent Foundation

20110065687 - Hydrazide compounds and uses thereof: This application relates to certain novel polycyclic compounds that interact with quadruplex-forming regions of polynucleotides and thereby inhibit translation of genetic information into polypeptides. These compounds can thus provide anticancer and antibacterial and antiviral effects. The invention includes novel compounds and pharmaceutical compositions, and methods of using them to treat... Agent:

20110065688 - Therapeutic piperazines: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in... Agent:

20110065689 - Therapeutic piperazines: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in... Agent:

20110065691 - Therapeutic piperazines: wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function... Agent:

20110065692 - Therapeutic pyrazolonaphthyridine derivatives: e

20110065693 - Therapeutic pyrazoloquinoline derivatives:

20110065694 - Histamine h3 inverse agonists and antagonists and methods of use thereof: Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release... Agent:

20110065695 - Use of aminodihydrothiazines for the treatment or prevention of diabetes: o

20110065697 - 2-oxy-benzoxazinone derivatives for the treatment of obesity:

20110065696 - Imidazoyl pyridine compounds and salts thereof: or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group or the like which may be substituted with a C1-6 alkyl group, Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group, X1 represents a double bond or the like and... Agent:

20110065698 - Novel protein kinase modulators: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention... Agent: Cylene Pharmaceuticals, Inc.

20110065699 - Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof: e

20110065700 - Polysubstituted derivatives of 6-heteroarylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof:

20110065701 - Pharmaceutical compounds: and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K with selectivity for the P110α subtype, and may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour, particularly those associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection,... Agent:

20110065702 - Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer: The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier... Agent: University Health Network

20110065704 - Compounds for modulating rna binding proteins and uses therefor: The invention relates to compositions and methods for inhibiting RNA binding proteins (e.g., MEX-3, MEX-5 and POS-1), as well as methods for treating and preventing disorders associated with parasitic infections and inflammatory disorders.... Agent:

20110065703 - Novel agents of calcium ion channel modulators: The present invention includes a group of chemical compounds useful as modulators of calcium ion (Ca2+) channels, especially for T-type, N-Type and L-type channels. The present invention also includes pharmaceutical compositions comprising these calcium ion channel modulating agents and methods of using these calcium ion channel modulating agents for the... Agent:

20110065705 - Compositions and methods of treating cell proliferation disorders: The invention relates to compounds and methods for treating cell proliferation disorders.... Agent:

20110065706 - Therapeutic agents 812: e

20110065707 - New hsl inhibitors useful in the treatment of diabetes:

20110065709 - Aurora kinase modulators and method of use: wherein A1-5 and 7-8, D′, L1, L2, R1, R3, R6-8, n and o are defined herein, and synthetic intermediates, which are capable of modulating the activity of Aurora kinase proteins and, thereby, influencing various disease states and conditions related to the activities of Aurora kinases. For example, the compounds are... Agent: Amgen Inc.

20110065708 - Heterocyclic oxime compounds: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for... Agent: Novartis Ag

20110065710 - Insecticidal n-(heteroarylalkyl)alkanediamine derivatives: Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U, V, X, WR6 and R7 are fully described herein. In addition, compositions comprising... Agent:

20110065711 - Substituted triazolo-pyridazine derivatives: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABAA receptor antagonist or an α2- and/or... Agent: Concert Pharmaceuticals, Inc.

20110065712 - Tricyclic compounds and pharmaceutical uses thereof: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.... Agent: Cylene Pharmaceuticals , Inc.

20110065713 - Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors: The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: High Point Pharmaceuticals, LLC

20110065714 - Substituted quinazolines: This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have... Agent: Shire LLC

20110065715 - Nogo receptor binding small molecules to promote axonal growth: The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the interaction of Nogo and Nogo receptor (NgR), the use of such compounds and compositions in the treatment or amelioration of conditions diseases... Agent: Yale University

20110065716 - Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors: The present invention provides compounds, including pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases, such as cancer.... Agent: Array Biopharma Inc.

20110065717 - Sulfoximine derivatives as factor xa inhibitors: The present invention relates to novel substituted sulfoximine derivatives of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation.... Agent: Cadila Healthcare Limited

20110065718 - Antifungal product, use and formulation thereof: An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more... Agent: Victory Pharma, Inc.

20110065719 - Pharmaceutical formulations containing flavouring substances with improved pharmaceutical: The invention relates to flavouring-containing pharmaceutical formulations with improved pharmaceutical properties, and to process for the production thereof.... Agent: Bayer Animal Health Gmbh

20110065720 - Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases: The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.... Agent: Abott Gmbh & Co Kg

20110065722 - A crystalline form of posaconazole: The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.... Agent: Sandoz Ag

20110065721 - Metaxalone products, method of manufacture, and method of use: Disclosed herein are methods of using metaxalone. In one embodiment, the method comprises determining that a patient in need metaxalone therapy is taking a substance that is a n inhibitor or an inducer of a cytochrome p450 isozyme, wherein the cytochrome P450 is CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or... Agent: Mutual Pharmaceutical Company, Inc.

20110065723 - Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-n-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide and uses thereof: The present invention relates to compositions of N-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl)acetyl]amino]-N-[3-(4-pyridyl)-1-[2-(4-pyridyl)ethyl]propyl]propanamide (Timcodar) useful for the treatment of patients with mycobacterium infections such as Mycobacterium tuberculosis. The invention also provides methods of treating patients with tuberculosis.... Agent: Vertex Pharmaceuticals Incorporated

20110065724 - Compounds that modulate intracellular calcium: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel... Agent: Calcimedica, Inc.

20110065725 - Triazole amide derivatives for use in therapy: The invention relates to triazole amide derivatives of formula (I) for use in therapy, in particular for treating diseases and conditions mediated by antagonism of the mGluR5 receptor, in particular substance related disorders. The invention also relates to certain novel derivatives. In addition, the invention relates to compositions containing the... Agent: Glaxo Group Limited

20110065726 - Organic compounds: e

20110065727 - Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof:

20110065728 - Lipoprotein lipase-activating compositions comprising benzene derivatives:

20110065730 - 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines: The invention relates to novel 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.... Agent:

20110065729 - Methods and compositions for ameliorating the undesirable effects of chemotherapy: In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at... Agent: Sound Pharmaceuticals Incorporated

20110065731 - Uses of dpp-iv inhibitors: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is... Agent: Boehringer Ingelheim International Gmbh

20110065732 - Kit for topical application of medication: The application describes a convenient portable kit for the application of topical medications. The kit can be used, for example, as a convenient system for application of cold sore medication. The kit includes a container for a quantity of fluid medication sufficient for several treatments together with a plurality of... Agent: Novartis Ag

20110065733 - Mapk/erk kinase inhibitors: e

20110065736 - Quinazoline derivatives as vegf inhibitors: The invention relates to quinazoline derivatives of formula (I), wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3 (wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected... Agent: Astrazeneca Ab

20110065734 - Novel bifunctional compounds which inhibit protein kinases and histone deacetylases: The present invention relates to a bifunctional compound of formula I or its pharmaceutically acceptable salts or solvates A-L-B (I) wherein A is a histone deacetylase (HDAC) inhibitory moiety, L is a single bond or a linker group and B is a protein kinase inhibitory moiety. The bifunctional compound according... Agent: 4sc Ag

20110065735 - Substituted quinazolines: This invention relates to the discovery of substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the... Agent: Shire LLC

20110065737 - Hcv protease inhibitors: This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.... Agent: Taigen Biotechnology Co., Ltd.

20110065738 - Polycyclic guanine derivatives and use thereof: The present invention relates to Polycyclic Guanine Derivatives, compositions comprising the Polycyclic Guanine Derivatives and methods of using the Polycyclic Guanine Derivatives to treat pain or an inflammatory disease.... Agent: Schering Corporation

20110065739 - Novel isoxazole drivative: Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an agonistic activity on GPR120 and is therefore useful for the treatment of diabetes, obesity or hyperlipemia. [In formula (I), the A represents a phenyl group which may be substituted by a lower alkoxy... Agent:

20110065740 - Methods of treating travelers diarrhea and hepatic encephalopathy: Treatment of traveler's diarrhea using in subjects having hepatic encephalopathy using gastrointestinal specific antibiotics is disclosed. One example of a gastrointestinal specific antibiotic is rifaximin.... Agent: Salix Pharmaceuticals, Ltd.

20110065741 - Methods for treating irritable bowel syndrome (ibs): The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.... Agent: Salix Pharmaceuticals, Ltd.

20110065742 - Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high ph environments: Immediate release compositions and methods for delivering drug formulations using weak acid ion exchange resins in abnormally high pH environments.... Agent:

20110065743 - Kappa opioid receptor ligands: Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.... Agent: Research Triangle Institute

20110065744 - Method of inhibiting mucin secretion: A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.... Agent: Reckitt Benckiser Inc.

20110065745 - Polysubstituted 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, and preparation and therapeutic use thereof: m

20110065746 - Composition of solifenacin or salt thereof for use in solid formulation: A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with... Agent: Astellas Pharma Inc.

20110065748 - Compositions and methods for treating disorders of gastrointestinal motility: Disclosed are methods of treating disorders of gastrointestinal motility by administering to a patient in need of such treatment a compound having the following formula:... Agent: Allergan, Inc.

20110065747 - Compositions and methods for treating seizure disorders: Disclosed are methods of treating a seizure disorder by administering to a patient in need of such treatment a compound having the following formula:... Agent: Allergan, Inc.

20110065749 - Method and pharmaceutical composition for treatment of mental disorders: A method of treating a mental disorder including administering to a patient in need thereof, an effective amount of a pharmaceutical composition including 1,1-diphenyl-4-piperidine-1-ylbuthan-1-ol or a pharmaceutically acceptable salt thereof. The mental disorder is depression, bipolar disorder, anxiety disorder, impulsive disorder, bulimia, panic disorder, social anxiety disorder, insomnia, attention deficit... Agent: Active Co. Ltd.

20110065750 - Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and methods of making the same: The present invention provides for new crystalline and amorphous forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, and methods of making the same.... Agent: Scinopharm Taiwan Ltd.

20110065751 - Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet... Agent: Pharmathen S.a.

20110065754 - Iminosugars and methods of treating filoviral diseases: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Filoviridae family using iminosugars, such as DNJ derivatives.... Agent: University Of Oxford

20110065752 - Methods of treating orthomyxoviral infections: Provided are novel iminosugars and methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Orthomyxoviridae family using iminosugars, such as DNJ derivatives.... Agent: University Of Oxford

20110065753 - Methods of treating poxviral infections: Provided are methods of treating a disease or condition caused by or associated with a virus belonging to the Poxyiridae family using iminosugars, such as DNJ derivatives.... Agent: University Of Oxford

20110065755 - Stable r(+)-lansoprazole amine salt and a process for preparing the same: A stable R-(+)-lansoprazole alkylamine salt and a process for preparing the salt.... Agent: Watson Pharma Private Limited

20110065756 - Methods and compositions for treatment of obesity-related diseases: The invention relates to methods, compositions, and kits for combination therapy of diabetes and diabetes-related diseases and conditions (e.g., obesity). The invention finds use in patients suffering from or at risk for diabetes or diabetes-related conditions generally, and in patients also suffering from or at risk for fluid retention (e.g.,... Agent:

20110065757 - Methods for treatment of kallikrein-related disorders: We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with... Agent: Activesite Pharmaceuticals, Inc.

20110065758 - Compositions and assays for treatment and diagnosis of helicobacter pylori infection and conditions: Methods of diagnosing Helicobacter pylori infection or associated conditions are based in part on the correlation of the presence of a α-L-fucosidase 2 marker with the infection. Methods and compositions for treating or preventing Helicobacter pylori infection or associated conditions are based in part on administering an α-L-fucosidase 2 inhibitor... Agent:

20110065759 - 5-(3,4-dichloro-phenyl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide and salts thereof: t

20110065760 - Compounds for the inhibition of rotamases and use thereof: The present invention is related to a compound of the formula (I), (II), (III), (IV), (V): wherein Z1, Z2, Z3 and Z4 are each and independently selected from the group comprising C(O)—, —C(S)—, —C(O)—NR10—, —C(S)—NR11—, —C(N—CN)—NR12—, —S(O)—, —S(O2)—, —S(O)—NR13—, and S(O2)—NR14—, —O—, —S— or are each and individually absent; X... Agent: Jerini Ag

20110065761 - Methods of treating nerve-related vision disorders: This invention provides reagents and methods for delivering insulin, insulinomimetic agents, and the like to a vertebrate eye via subconjunctival routes, sub-Tenon's routes, or intravitreal routes for treatment of nerve-related vision disorders such as diabetic retinopathy, and formulations useful in the practice of the disclosed methods... Agent: The Penn State Research Foundation

20110065762 - Methods of use of antiviral compounds: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3... Agent:

20110065763 - Compositions for topical application having androgenic actions: e

20110065764 - 5- phenyl-isoxazole-3-carboxamide derivatives as trpv1 modulators: The present invention relates to isoxazole-3-carboxamide derivative having the general Formula (I), or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of said isoxazole-3-carboxamide derivatives for the treatment of TRPV1 mediated disorders, such as acute and chronic pain disorders, acute and... Agent: N.v. Organon And Pharmacopeia, LLC

20110065765 - Angiotensin ii receptor antagonists: e

20110065766 - Methods of use of antiviral compounds: The present invention relates, in part, to methods of treatment, prevention, and inhibition of viral disorders. In one aspect, the present invention relates to inhibition of the M2 proton channel of influenza viruses (e.g. influenza A virus) and other similar viroporins (e.g., VP24 of Ebola and Marburg viruses; and NS3... Agent:

20110065767 - Substituted cc-1065 analogs and their conjugates: This invention relates to novel agents that are analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and their conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a... Agent:

20110065768 - Non-steroidal androgens compounds: i

20110065769 - Transdermal delivery of ionizable drugs: Provided is a composition for transdermal administration. The composition comprises a therapeutic agent having a net charge at skin pH and a topical penetration enhancer having a net charge at skin pH opposite the net charge of the therapeutic agent. In another aspect, a method is provided for increasing the... Agent:

20110065781 - Alpha-lipoic acid nanoparticles and methods for preparing thereof: Provision of a stable α-lipoic acid. A method for producing α-lipoic acid nanoparticles, the method comprising the steps of: preparing an aqueous dispersion liquid containing α-lipoic acid and a nonionic surfactant; adding a divalent metal salt into the aqueous dispersion liquid, wherein the divalent metal salt is a divalent metal... Agent: Nanoegg Research Laboratories, Inc.

20110065782 - Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds: The present invention relates to methods of identifying compounds that inhibit the activation between a biomolecule, pharmaceutical compositions comprising such compounds, and methods of treating and/or to reducing the risk of Bacillus anthracis and Bordetella pertussis infection by administering such pharmaceutical compositions.... Agent:

20110065783 - Hydroxylated nebivolol metabolites: Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration.... Agent:

20110065784 - Method for promoting gastrointestinal bicarbonate secretion: d

20110065785 - Non-sterile fermentation of bioethanol.: A range of concentrations exists in which fermentation inhibitors derived from pretreatment of lignocellulosic feed stocks inhibit growth of lactic acid bacteria without affecting fermentive yeast. By optimizing levels of fermentation inhibitors to fall within this range, yeast fermentations of lignocellulosic biomass can be conducted under non-sterile conditions with ethanol... Agent:

20110065786 - Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species: The present invention provides new strategies for the synthesis of compounds of the rocaglamide family and related natural products. In particular, the new biomimetic synthetic approach involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile. This approach... Agent:

20110065787 - Therapeutic agent for male sterility: e

20110065788 - Aqueous formulations of (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorobutane-1-sulfonate: The invention relates to aqueous formulations containing (−)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate. Said formulations are suitable as infusion solutions or as concentrate for producing these infusion solutions.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110065789 - Ester compound and use thereof: e

20110065790 - Latanoprost-containing aqueous pharmaceutical composition: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least... Agent: Wakamoto Pharmaceutical Co.,ltd.

20110065791 - System for aroma release: The invention concerns a process for preparing particles, which particles contain one or more spaces in which a gas phase is present which comprises at least one active ingredient, in particular at least one aroma, flavor or precursor for an aroma or flavor, and which space or spaces are at... Agent:

20110065792 - Novel substances analogous to mk8383 and agricultural and horticultural disease control agents: An objective of the present invention is to provide agricultural and horticultural disease control agents that have potent control effect against plant diseases and, at the same time, have high photostability. The agricultural and horticultural disease control agents comprise a novel substance analogous to MK8383 as an active ingredient.... Agent:

20110065793 - Highly purified ethyl epa and other epa derivatives: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA... Agent: Amarin Corporation PLC.

20110065794 - Wrinkle-preventing and improving composition: wherein, R1 represents hydrogen atom, CH3 group or CH2OH group, R2 and R3 each independently represent hydrogen atom, alkyl group having 1 to 4 carbons, provided that R2 and R3 cannot be hydrogen atom at the same time, or R2 and R3 together with N atom to which they are... Agent: Shiseido Company, Ltd.

20110065795 - (1s,2s,3s,4r)-3-[(1s)-1-acetylamino-2-ethyl-butyl]-4-uanidino-2-hydroxyl-cyclopentyl-1-carboxylic acid hydrates pharmaceutical uses thereof: The present invention relates to (1S,2S,3S,4R)-3-[(1S)-1-acetylamino-2-ethyl-butyl]-4-guanidino-2-hydroxy-cyclopentyl-1-carboxylic acid hydrates compounds, preparing methods thereof, pharmaceutical compositions containing said compounds and preparing methods thereof, and the clinical uses of said compounds as neuramidinase inhibitors for anti-influenza.... Agent:

20110065797 - Deloxiglumide and proton pump inhibitors combination in the treatment of gastrointestinal disorders: Cholecystokinin-1 (CCK1) receptor antagonists and the combination of CCK1 receptor antagonists and proton pump inhibitors (PPI) for the treatment of patients suffering from gastrointestinal or related disorders that have failed to completely respond to conventional acid suppression therapy.... Agent: Rottapharm S.p.a

20110065796 - Prodrugs of guanfacine: Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side... Agent: Shire LLC

20110065798 - Anti-infective lubricant for medical devices and methods for preparing the same: A lubricious antiseptic coating material containing various solvents to achieve mutual miscibility and provide a generally homogenous product. A coating material is provided having an antipathogenic agent and a solvent for dissolving the same. The coating further includes a lubricious agent and a solvent for dissolving the same. Thus, the... Agent: Becton, Dickinson And Company

20110065799 - Urokinase inhibitors, production and use thereof: The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.... Agent: The Medicines Company (leipzig) Gmbh

20110065800 - Formulations for cathepsin k inhibitors: The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.... Agent:

20110065801 - Enzymatic synthesis of sphingolipids: The invention relates to the enzymatic synthesis of sphingolipids and compositions comprising sphingolipids from lysosphingolipids and carboxylic esters, and to cosmetic, dermatological or pharmaceutical formulations which comprise these sphingolipids or compositions.... Agent: Evonik Goldschmidt Gmbh

20110065802 - Chelator stabilized cationic ammonium compounds and compositions comprising the same: Stabilized cationic ammonium compounds are described. The compounds are stabilized with pyridine-based chelators and/or heteroketo-based chelators that impede the generation of nitrogen comprising groups from the cationic ammonium compounds.... Agent: Conopco, Inc., D/b/a Unilever

20110065803 - Stabilized compositions of volatile alkylating agents and methods of using thereof: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include... Agent: Yaupon Therapeutics, Inc.

20110065804 - Electrodeposited metallic finishes including antimicrobial agents: Articles having metallic finishes including antimicrobial agents dispersed throughout the finish and methods of electroplating said metallic finishes on a material. The metallic finishes include highly-decorative electroplated finishes for bathroom and kitchen hardware, door hardware, and other highly lustrous products where antimicrobial protection is preferred.... Agent: Microban International Ltd.

20110065805 - Xanthophyll composition containing macular pigments and a process for its preparation: A xanthophyll composition that contains macular pigments including trans-lutein and zeaxanthin isomers, namely, (R,R)-zeaxanthin and (R,S)-zeaxanthin, derived from the plant extract/oleoresin containing xanthophylls/xanthophylls esters which is safe for human consumption and useful for nutrition and health care. The composition has at least 80% by weight that is total xanthophylls, of... Agent: Omniactive Health Technologies Limited

20110065806 - Emollient composition for the preventive treatment of atopic dermatitis: The invention relates to a composition for topical use that comprises a combination of glycerol, Vaseline and liquid paraffin as an active principle, in the form of an oil-in-water or water-in-oil emulsion, said composition being used in the prevention of atopic dermatitis.... Agent: Pierre Fabre Dermo-cosmetique

20110065808 - Carbonyl compound remover: A carbonyl compound remover comprising at least one polyether resin that includes a unit shown by any of the formulas (I) to (IV) as an active ingredient, a method of preventing coloration of an infusion comprising causing the carbonyl compound remover to come in contact with an infusion that may... Agent: Ajinomoto Co. Inc.

20110065807 - Ph sensitive biodegradable polymeric particles for drug delivery: The present invention generally relates to polymers and particles, such as nanoparticles. The particles and polymers generally include one or more buffering components. Additionally, the particles and polymers may include two or more components that impart useful properties (functionalities). The particles and polymers, for example, may include a buffering component... Agent: The Brigham And Women's Hospital, Inc.

20110065809 - Polymerization of multifunctional azides, and polymers therefrom: Methods for preparing polymers from multifunctional azides and multifunctional azide-reactants are described in the present disclosure. Exemplary multifunctional azide-reactants include multifunctional alkynes and/or multifunctional α-phosphine esters. In certain embodiments, such polymers can be prepared in vivo. Such polymers can be useful in a wide variety of biomedical applications.... Agent: Medtronic, Inc.

20110065810 - Use of alternan as texturizing agent in foodstuffs and cosmetics: The invention is directed to the use of alternan as a texturizing agent, particularly as a fat or oil replacer in foodstuffs or cosmetic preparations, a homogeneous composition comprising alternan and water, the use of the homogenous composition as a texturizing agent in foodstuffs or cosmetic preparations, and foodstuffs and... Agent: Bayer Cropscience Ag

  
03/10/2011 > patent applications in patent subcategories. listing by industry category

20110059885 - Treatment of diseases and conditions mediated by eicosanoids: The method of the invention relates to an OmCI polypeptide or a polynucleotide encoding an OmCI polypeptide for the treatment of a disease or condition mediated by a leukotriene or hydroxyeicosanoid.... Agent: Natural Environment Research Council

20110059886 - Hcv ns3-ns4a protease inhibition: The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life... Agent: Vertex Pharmaceuticals Incorporated

20110059887 - Meal-time insulin analogues of enhanced stability: A method treating a patient includes administering a physiologically effective amount of a fibrillation-resistant insulin analogue or a physiologically acceptable salt thereof to the patient. The fibrillation-resistant insulin analogue or a physiologically acceptable salt thereof, contains an insulin A-chain sequence modified at position A8 and an insulin B-chain sequence or... Agent: Case Western Reserve University

20110059888 - Metastin derivatives and use thereof: The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the... Agent: Takeda Pharmaceutical Company Limited

20110059889 - Peptides that block the binding of igg to fcrn: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to... Agent: Syntonix Pharmaceuticals, Inc.

20110059890 - Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas... Agent: Vegenics Limited

20110059891 - Alpha-msh therapies for treatment of autoimmune disease: Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment... Agent:

20110059892 - Cosmetic preparations containing pth fragments: where R1 is selected from the group consisting of —H, a linear or branched, saturated or unsaturated acyl group having from 1 to 24 carbon atoms optionally functionalized with an —OH, —SH, —COOH or —CONH2 group, or a sterol group which is bonded by a functional group with the peptide;... Agent:

20110059893 - Compounds for the treatment of proliferative disorders: e

20110059894 - Factor vii polypeptides for preventing formation of inhibitors in subjects with haemophilia: The invention provides a method for preventing formation of inhibitors to blood coagulation factor VIII or factor IX in a subject having haemophilia, the method comprising administering (via intravenous, subcutaneous, intradermal, or intramuscular routes) to a previously untreated subject an effective dosage of factor VIIa or a factor VII-related polypeptide.... Agent: Novo Nordisk A/s

20110059895 - Modulation of factor 9 expression: Disclosed herein are antisense compounds and methods for decreasing Factor 9 and increasing clotting time in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 9 include thrombosis, embolism, thromoboembolism such as deep vein thrombosis, pulmonary embolism,... Agent: Isis Pharmaceuticals, Inc.

20110059897 - Methods for treating a skin wound: A therapeutic method for treating a skin wound involving administering to a patient in need thereof a composition containing pharmaceutically effective amounts of the following components: (1) a peptide consisting of the amino acid sequence represented by Ser-Ser-Ser-Arg (SEQ ID NO: 1) or pharmaceutically acceptable salts thereof and (2) a... Agent: Santen Pharmaceutical Co., Ltd.

20110059896 - Use of furin convertase inhibitors in the treatment of fibrosis and scarring: The present invention relates to use of convertase inhibitors for the reduction of scarring during the healing of wounds and also for reducing fibrosis in the treatment of fibrotic conditions.... Agent: Renovo Limited

20110059901 - Compositions and methods for treatment of neoplastic disease: The present invention comprises compositions and methods for treating a tumor or neoplastic disease in a host, The methods employ conjugates comprising superantigen polypeptides or nucleic acids with other structures that preferentially bind to tumor cells and are capable of inducing apoptosis. Also provided are superantigen-glycolipid conjugates and vesicles that... Agent:

20110059900 - Diagnosing and treating hormone resistant cancers: Provided herein are methods and compositions related to diagnosing and treating hormone resistant cancers.... Agent: Board Of Regents, The University Of Texas System

20110059899 - Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein: The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.... Agent: Mount Sinai School Of Medicine Of New York University

20110059898 - Pro-oxidant anti-cancer compounds: This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In particular, the invention concerns pro-oxidant anti-cancer compounds, such as pro-oxidant forms of vitamin E, that selectively interact with complex II of the mitochondrial respiratory chain of cancerous cells, generate reactive oxygen species and induce apoptosis... Agent:

20110059902 - Therapeutic replenishment and enrichment of ocular surface lubrication: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant... Agent: Schepens Eye Research Institute

20110059903 - Formulations comprising linaclotide: The present invention relates to stable compositions comprising linaclotide, as well as to various methods and processes for the preparation and use of the compositions.... Agent: Forest Laboratories Holdings Limited

20110059904 - Serum-based, diagnostic, biological assay to predict pregnancy disorders: The invention provides serum-based, diagnostic, biological assays for predicting disorders of pregnancy resulting from poor trophoblast and/or placental ischemia, including preeclampsia. Serum samples from such subjects exhibit an ability to disrupt the architecture involving fetal trophoblasts and maternal endothelial cells in a three-dimensional, dual cell co-culture system provided herein, in... Agent: Brown University

20110059905 - Methods of treating disease-induced ataxia and non-ataxic imbalance: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.... Agent:

20110059907 - Chiral complexes of ascorbic acid with natural antioxidant and anti-inflammatory ketones including aloe, citrus, ginger, and mango for skin and hair care: This invention relates to certain complexes of ascorbic acid and its derivatives with certain natural antioxidant and anti-inflammatory ketones for topical or oral application; said complexes having general chemical formula (I), its isomers, and salts thereof, including their optically active or racemic forms. This invention also relates to a method... Agent: Island Kinetics Inc.

20110059906 - Energy status of an individual by enhanced production of an endogenous fuel source: The present invention relates to a method of improving the energy status of an individual by enhancing the usage of lactate. Improved lactate usage is accomplished through a composition comprising lactate precursors, adrenergic receptor agonists and insulinotropic agents.... Agent: Northern Innovations And Formulations Corp.

20110059911 - Antiinfective and antitumoral compounds isolated from tropical lianas: The present invention relates to naphthoquinone derivatives isolated from solid callus cultures from two species of the palaeotropical plant families Dioncophyllaceae and Ancistrocladaceae. It further relates to methods of their production as well as to their use as antiinfective and antitumoral pharmaceuticals.... Agent:

20110059908 - Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax: The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising... Agent: Isis Innovation Limited

20110059909 - Methods for treating inflammatory disorders: The present invention relates generally to the fields of molecular biology. More particularly, it concerns materials and methods for the treatment of nitric oxide and cytokind mediated disorders. In a preferred embodiment, PDMP may be used to inhibit the expression of iNOS and pro-inflammatory cytokines such as TNFα and IL1β.... Agent:

20110059910 - Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof: The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.... Agent: Sanofi-aventis

20110059912 - Combination therapy comprising sglt inhibitors and dpp4 inhibitors: The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.... Agent:

20110059913 - Compositions and methods for the treatment of gastrointestinal indications: The present invention relates to identification of Oroxylum indicum, Indian medicinal plant as a rich source for flavanoid compounds. Mucoprotective and antigastric ulcer properties in the flavone class of compounds isolated therefrom have been identified along with a flavanoids mixture in substantial yields from hexane and acetone extracts. The hexane... Agent: Council Of Scientific And Industrial Research

20110059914 - Stable needle-shaped crystals of natamycin: Stable needle shaped crystals of natamycin having a mean length of between 0.1 and 20 μm.... Agent: DsmIPAssets B.v.,

20110060027 - Aptamer therapeutics useful in the treatment of complement-related disorders: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.... Agent:

20110060028 - Combination therapy: This disclosure relates to a SIRT1 polypeptide and a treatment regime that inhibits the activity of SIRT1 and including a method of diagnosis.... Agent: University Of York

20110060031 - Compositions and methods for inhibiting expression of a gene from the ebola virus: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.... Agent: Alnylam Pharmaceuticals, Inc.

20110060033 - Fertility restorer gene and fertility restoration method for cw-type male sterile cytoplasm of rice: Mainly provided is a technique for directly identifying the genotype at locus Rf17 based on the specific base sequence data thereof. Also provided is a technique for artificially constructing a fertility-restored line. A method of restoring the fertility of CW-type cytoplasmic male sterile rice by inhibiting or reducing the expression... Agent:

20110060032 - Lipid encapsulating interfering rna: The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.... Agent: Protiva Biotherapeutics, Inc.

20110060029 - Method of treating cancer by modulating epac: Methods of treating cancer by preventing, mitigating, and/or inhibiting cancer metastasis in tumors expressing Epac by inhibiting the activity of exchange proteins directly activated by cyclic AMP (Epac) or one or more proteins within the Epac-induced carcinoma migration pathway.... Agent:

20110060030 - Modulation of apolipoprotein c-iii expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided... Agent: Isis Pharmaceuticals, Inc.

20110060034 - Cell transdifferentiation into brown adipocytes: A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting... Agent: Miami University

20110060035 - Preventing and treating amyloid-beta deposition by stimulation of innate immunity: The present invention is directed to a method of preventing or reducing amyloid deposition in a subject. This method involves selecting a subject with amyloid deposits and stimulating the innate immune system of the selected subject under conditions effective to reduce the amyloid deposits. Also disclosed is a method of... Agent: New York University

20110059915 - Purine derivatives and methods of use thereof: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering... Agent: Inotek Pharmaceuticals Corporation

20110059916 - Methods and compositions for inducing torpor in a subject: The present invention relates to the discovery the 5′-AMP and analogues thereof can be used to induce a state of torpor or suspended animation in subjects, as exemplified by studies carried out in laboratory mice. In these studies; mice were injected with high doses of 5′-AMP, which was found to... Agent:

20110059917 - Vitamin d3 and analogs thereof for treating alopecia: The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the... Agent:

20110059919 - Antiviral composition comprising a sulfated polysaccharide: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus... Agent: Marinomed Biotechnologie Gmbh

20110059918 - Stable hyaluronan/steroid formulation: A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.... Agent:

20110059920 - Agent for regeneration and/or protection of nerves: An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet... Agent: Ono Pharmaceutical Co., Ltd

20110059921 - Oligomer-nitrogenous base conjugates: The invention relates to (among other things) oligomer-nitrogenous base conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over unconjugated nitrogenous base compounds.... Agent: Ektar Therapeutics

20110059922 - Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers: The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups.... Agent: Medical College Of Wisconsin, Inc.

20110059923 - Novel phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders containing the same as an active component: The present invention relates to a novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof, a production method therefor and a pharmaceutical composition for preventing and treating central nervous system disorders which contains the same as an active component. The novel {4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenoxy}phosphate or a pharmaceutically acceptable salt thereof according to the... Agent: Je Il Pharmaceutical Co., Ltd.

20110059924 - Chemoprevention of colorectal cancer by mesalamine/sulfasalazine: A method for preventing or treating colorectal cancer in a patient possessing human tropomyocin isoform TC22 is presented. Also presented is a method for evaluating TC22 expression reduction activity of a compound.... Agent: University Of Medicine And Dentistry Of New Jersey

20110059925 - Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics: The present invention provides a mucoadhesive broad spectrum antibiotic with anti-inflammatory characteristics with strong tissue penetration for improving lid margin function and the treatment of diseases associated therewith. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of blepharitis and dry eye disease.... Agent:

20110059927 - Calcium formate for use as a dietary supplement: A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.... Agent: Wisconsin Alumni Research Foundation

20110059926 - Vitamin d compounds and methods for reducing ocular hypertension (oht): The present invention relates to compounds and methods for reducing intraocular pressure and treating ocular hypertension in a subject.... Agent:

20110059928 - Graduated estrogen contraceptive: A multiphasic estrogenic/progestogenic contraceptive regimen that provides for the reduction or elimination of estrogen in the initial phase is disclosed. Also described is a contraceptive kit that may be used to practice the method of the invention.... Agent: Warner Chilcott Company, LLC

20110059931 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, m, n, p, r, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and... Agent: Theravance, Inc.

20110059930 - Composition for the regulation of the human immune system and the prevention and treatment of diseases thereof: A nutritional supplement composed of phytosterols, anti-oxidants, and other complexes, including essential fatty acids, amino acids, peptides, proline rich polypeptides and digestive enzymes is described. The nutritional supplement may be used by individuals suffering from or at risk of developing immune system diseases; breast cancer, colon and prostate cancer; HIV... Agent:

20110059929 - Substituted bicyclic piperidinyl-and piperazinyl- sulfonamides useful to inhibit 11beta-hydroxysteroid dehydrogenase type-1: In its many embodiments, the present invention relates to a novel class of substituted bicyclic piperidinyl- and piperazinylsulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase... Agent: Schering Corporation

20110059932 - Liver x receptor agonists: in which R1, R2, R3, R3′, R4, R5, R6, R6′, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, A, D, X, Y, and Z are defined in the specification. Also disclosed is a method of using one of the compounds to lower the blood cholesterol level and... Agent: The University Of Chicago

20110059933 - Crystalline sodium salt of cephalosporin antibiotic: The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).... Agent: Orchid Chemicals & Pharmaceuticals Limited

20110059935 - Beta-lactamyl vasopressin v1a antagonists: Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.... Agent: Azevan Pharmaceuticals, Inc

20110059936 - C-met protein kinase inhibitors: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides processes for preparing the compounds of this invention, pharmaceutically acceptable compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110059934 - Compounds and compositions useful for the treatment of parasitic diseases: The invention provides a class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent malaria.... Agent: Irm LLC

20110059939 - Therapeutic compounds: Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, a dashed line represent the presence or absence of a double bond, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-12. Methods, compositions, and medicaments related thereto are also disclosed, for treating glaucoma,... Agent: Allergan ,inc

20110059940 - 2-aryl glycinamide derivatives: The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide (β-AP) production.... Agent: Bristol- Myers Squibb Company

20110059941 - 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators: Compounds of Formula (I), wherein R1-R10, A and X1 to X3 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.... Agent:

20110059942 - Azetidinyl g-protein coupled receptor agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.... Agent:

20110059944 - Certain substituted amides, method of making, and method of use thereof: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity... Agent:

20110059943 - Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer: m

20110059945 - S1p receptor modulating compounds and use thereof: The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e.g., for treating or preventing diseases such as autoimmune... Agent: Epix Pharmaceuticals, Inc.

20110059937 - Il-8 receptor antagonists: This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).... Agent: Smithkline Beecham Corporation

20110059938 - New chemical compounds: i

20110059946 - Dual action antibiotics: The present invention relates to compounds of the Formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:... Agent: Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie

20110059947 - Alpha 7 nicotinic agonists and antipsychotics: The present invention relates to a synergistic combination of an alpha7 (α7) nicotinic agonist and an antipsychotic agent.... Agent: Targacept, Inc.

20110059948 - Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents: The invention relates to a compound of general formula I, II, III, IV, V, VI, VII, VIII, IX, X or a tautomer and the stereochemically isomeric forms thereof or pharmaceutically acceptable salts thereof, a N-oxide form thereof or a pro-drug thereof. The compound is usable as a medicament for the... Agent:

20110059949 - Prophylaxis and treatment of infectious diseases: The invention relates to the use of inhibitors of acid sphingomyelinase and/or of inhibitors of products of the reaction catalyzed by this enzyme, for the prophylaxis and/or treatment of infectious diseases and/or diseases which are influenced by infections during the course thereof. The cited products especially include ceramide. Preferrably neutralizing... Agent:

20110059950 - Aniline derivative having anti-rna viral activity: Viruses, and particularly RNA viruses, have high mutation rates. Hence, antiviral agents that have been developed to date targeting protease or reverse transcriptase of viruses have quickly lost their effectiveness and resistant viruses have emerged. Also, in recent years, viral diseases caused by various new viruses such as SARS, avian... Agent: Kinopharma, Inc.

20110059952 - 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to,... Agent: Mimetica Pty Ltd

20110059953 - Compounds for use in stabilizing p53 mutants: Compounds of formula (I): wherein X is selected from CRX and N; RN1 is selected from H and C1-4 alkyl, which may be substituted by SH or halo; RG1 is selected from H and SH; RC2 is selected from H and optionally substituted C1-7 alkyl; RC3 is selected from H... Agent:

20110059951 - Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors: The present invention provides heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.... Agent:

20110059954 - Cgrp antagonists: wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Boehringer Ingelheim International Gmbh

20110059955 - Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof: e

20110059956 - Therapeutic agent for pain:

20110059957 - Benzene or thiophene derivative and use thereof as vap-1 inhibitor: The present invention provides a novel benzene derivative or thiophene derivative useful as a VAP-1 inhibitor, or a medicament for the prophylaxis or treatment of a VAP-1 associated disease and the like, namely, a compound represented by the formula (I): wherein each symbol is as defined in the present specification,... Agent: R-tech Ueno, Ltd.

20110059958 - Morpholinone compounds as factor ixa inhibitors: e

20110059959 - Novel multicyclic compounds and the use thereof: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer.... Agent: Cephalon, Inc.

20110059960 - Method of treating inherited severe neutropenia: The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.... Agent:

20110059961 - 4-substituted pyridin-3-yl-carboxamide compounds and methods of use: The invention relates to compounds of formula (I) which are useful as kinase inhibitors, more specifically useful as PIM kinase inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same, either alone or in combination,... Agent:

20110059963 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Plexxikon, Inc.

20110059962 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of using substituted benzimidazole compounds, in, e.g., reducing virulence and infectivity, inhibiting biofilms and treating bacterial infections, are also provided.... Agent:

20110059965 - Bicyclic derivatives as modulators of ion channels: Bicyclic derivatives having formula (I) and a composition thereof are useful as ion channel antagonists:... Agent: Vertex Pharmaceuticals Incorporated

20110059966 - Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders: This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3 histamine receptor antagonist activity. This invention also relates to... Agent:

20110059964 - Pyrazole derivatives and use thereof as orexin receptor antagonists: The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.... Agent: Sanofi-aventis

20110059967 - Therapeutic compounds: Compounds comprising Formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-16. Methods, compositions, and medicaments related thereto are also disclosed, for treating glaucoma, inflammatory bowel disease and baldness.... Agent: Allergan Inc.

20110059968 - Carboxamide compounds and their use as calpain inhibitors: m

20110059969 - Piperazines as anti-obesity agents: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds, to processes for their preparation, and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.... Agent: Astrazeneca Ab

20110059970 - 4-phenyl-1,3-thiazoles and 4-phenyl-1,3-oxazoles derivatives as cannabinoid receptor ligands: wherein R1, R2, R3, R4, X, A, B, and n are variable, in a racemic form, an enantiomeric form or any combinations thereof. These compounds exhibit affinity for cannabinoid receptors and may therefore be used as drugs to treat or prevent pathological states and diseases in which one or more... Agent: Ipsen Pharma S.a.s.

20110059971 - Derivatives of 4-aminopiperidine and their use as a medicament: in which R1, R2 and R3 represent various radical, and their preparation processes by synthetic methods in parallel in liquid and solid phase. These products having a good affinity with certain sub-types of somatostatin receptors, they are particularly useful for treating the pathological states or diseases in which one (or... Agent: Ipsen S.a.s.

20110059972 - 1,4-naphthoquinones derivatives and therapeutic use thereof:

20110059974 - Novel retinamide retinoic acid metabolism blocking agents: Retinoic acid metabolism blocking agents (RAMBAs). The RAMBAs may be used for treatment of cancer, including breast and prostate cancers. Methods for preparing novel retinamide RAMBAs. The methods include reacting RAMBAs with terminal polar carboxylic acid group with a variety of amines in the presence of suitable coupling reagents. The... Agent: University Of Maryland, Baltimore

20110059973 - Pyrazole compounds for controlling invertebrate pests: t

20110059975 - Non-nucleoside reverse transcriptase inhibitors: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein A is A2 and R1, R2, R3, R4a, R4b, R5, R6, Ar, X1, X2, X4, X4 and X5... Agent:

20110059976 - Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors: n, R1, R2, R3, R4, L1, L2, Y and Z are as defined in classes and subclasses herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., RAF), and thus are useful, for example, for the treatment of... Agent:

20110059977 - Use of canthin-6-one and its analogs in the treatment of mycobacteria-linked pathologies ( amended: The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and... Agent: Institut De Recherche Pour Le Developpement (i.r.d.)

20110059978 - Pyridazinyl amine derivatives, the use thereof in the preparation of picorna virus inhibitors: The present invention relates to substituted pyridazinylamine derivatives of the formula I or pharmaceutically acceptable salts or hydrates thereof, wherein the substituents are defined as in the description, their preparation process, pharmaceutical compositions comprising them, and uses of the said compounds as picorna virus inhibitors for prevention and/or treatment of... Agent:

20110059979 - Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators: e

20110059980 - Solid preparation for oral administration: Disclosed is a solid preparation for oral administration, which comprises cariprazine hydrochloride, in which lactose is used as the main excipient, and which enables the stable storage of cariprazine hydrochloride contained therein without the need of adding cyclodextrin.... Agent:

20110059982 - Azaindole compounds for treatment of central nervous system disorders: Azaindole derivative compounds are described. The compounds have an optionally substituted azaindole core linked to a carbocyclic ring having at least one nitrogen atom and further bound to an optionally substituted aryl ring. A process for preparing these compounds, compositions comprising them, and methods of using them to treat disorders... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110059983 - Use of substituted oxindole derivatives for the treatment and prophylaxis of pain: The present invention relates to the use of substituted oxindole derivatives of formula I as defined in the claims and description for the treatment or prophylaxis of pain.... Agent: Abbott Laboratories

20110059981 - New pyridine analogues v: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.... Agent: Astrazeneca Ab

20110059984 - Heterocycles useful as modulators of ion channels: The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110059986 - Intermittent dosing regimen for overweight and obese subjects: The present invention concerns an intermittent dosing regimen for the treatment of obesity or the reduction of body weight wherein a pharmaceutical composition containing an apoB secretion/MTP inhibitor is administered to a subject in need thereof for a period of time, then withheld for a period of time, and again... Agent:

20110059985 - Novel formulation: The present invention relates to a pharmaceutical formulation comprising a pharmaceutically activeagent; water; a polyethylene glycol or a poloxamer; and a polyethylene glycol mono- or di-ether. Preferably the pharmaceutically active agent is an anti-fungal or anti-mycotic agent. Preferably the pharmaceutically active agent is lipophilic and/or keratinophilic. The present invention also... Agent:

20110059989 - 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of airway diseases: in free or salt or solvate form, where R1, R2, R3, R4, R5, R6, R7, R8 and R9 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for... Agent:

20110059987 - Co-crystals and pharmaceutical compositions comprising the same: The invention relates to compositions and co-crystals each comprising VX-950 and a co-crystal former selected from the group consisting of 4-hydroxybenzoic acid, 4-amino salicylic acid, phenylalanine, threonline, tartaric acid, adipic acid, succinic acetate, proline, methyl 4-hydroxybenzoate, anthranilic acid, and d-Biotin. Also within the scope of this invention are methods of... Agent: Vertex Pharmaceuticals Incorporated

20110059988 - Isoxazoline compositions and their use as antiparasitics: This invention relates to methods for controlling parasitic infestations of animals and their environments, and, more particularly, to methods using isoxazolines to control parasites in or on animals or in their environments, as well as treat parasitoses of animals. The isoxazolines include 4-(isoxazolinyl)-benzamides (specifically, substituted 4-(5-(halomethyl)-5-phenylisoxazolin-3-yl)-benzamides) and 4-(isoxazolinyl)-benzothioamides (specifically, substituted... Agent: Intervet International B.v.

20110059992 - New compounds: i

20110059991 - Selective insecticides based on anthranilic acid diamides and safeners:

20110059990 - Substituted phenyl(oxy/thio)alkanol derivatives: The present invention relates to novel substituted phenyl(oxy/thio)alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.... Agent: Bayer Cropscience Ag

20110059993 - 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1h-pyrazolo[4,3-d]pyrimidin-5-yl) piperidine-4-carboxylic acid and salts thereof: The present invention comprises 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical compositions, methods of treatment, and synthetic methods relating to 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts.... Agent: Pfizer Inc.

20110059994 - Composition for preventing or treating brain cancers: A composition for preventing and/or treating brain tumor, containing caffeine and/or its analog, and/or their pharmaceutically acceptable salt, as an active ingredient, is provided. The composition for preventing or treating brain tumor has an activity to inhibit invasion, migration, and proliferation of brain tumor cells, and thereby very effective for... Agent: Korea Institute Of Science And Technology

20110059995 - Substituted xanthine derivatives: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent: Concert Pharmaceuticals Inc.

20110059996 - Novel pyrrolo [3, 2-d] pyrimidin-4-one derivatives and their use in therapy: wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis... Agent:

20110059997 - Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-ht6 receptors and methods for production and the use thereof: e

20110059998 - Kit, composition, product or medicament for treating cognitive impairment: A kit, composition, product or medicament for treating cognitive impairment is provided, which includes a therapeutic agent for neurodegenerative disease and a heterocyclic compound represented by the following General Formula (I): or a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.... Agent: Zenyaku Kogyo Kabushiki Kaisha

20110059999 - Hydroxymethylcyclohexylamines: The invention relates to compounds which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.... Agent: Gr&#xdc Nenthal Gmbh

20110060000 - Acridine analogs in the treatment of gliomas: Disclosed are methods and compositions for treating gliomas that involve quinacrine and other acridine analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.... Agent:

20110060001 - Thienopyridone derivatives as amp- activated protein kinase (ampk) activators: The present invention relates to compounds of formula (I) wherein R1, R2 and B1, B2 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and... Agent:

20110060002 - Conglomerates of tenatoprazole potassium salts: The invention relates to conglomerates of tenatoprazole potassium salts of the following general formula (I), that consist of an equimolar mixture of enantiomers having R and S configurations and capable of crystallisation in the form of a conglomerate, wherein said salts are selected from tenatoprazole dehydrated potassium salt, tenatoprazole potassium... Agent: Sidem Pharama Sa

20110060004 - Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors: Compounds of formula (I): in free or salt or solvate form, where X, R1, R2, R3 and R4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds... Agent: Novartis Ag

20110060003 - Lonidamine analogues for fertility management: Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis... Agent:

20110060005 - Treatment of mitochondrial disorders using a farnesyl transferase inhibitor: Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies and mitochondrial disorders are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject an... Agent: Link Medicine Corporation

20110060006 - Functionally selective alpha2c adrenoreceptor agonists: In its many embodiments, the present invention provides a novel class of heterocyclic derivatives as a2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or... Agent: Schering Plough Corporation

20110060007 - Novel nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydroge-nase-1: The present invention relates to NIP thiazole derivatives of formula (I) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders,... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftling

20110060008 - Pharmaceutical composition containing acetylcholine esterase inhibitor and method for the preparation thereof: A pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof, and an effective amount of pH dependent excipient as a taste masking agent, to suppress the release of donepezil in the pH environment of the oral cavity and increase the release of donepezil in acidic environment.... Agent:

20110060009 - Hydroxamate-based inhibitors of deacetylases: p

20110060010 - Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof: The present invention provides a pharmaceutically acceptable strong acid salt of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione, a solvate thereof, a process for preparing the same and use in the preparation of a medicament for treating diseases or physiological abnormities by inhibiting inflammatory factors or angiogenesis. The water-solubility of the pharmaceutically acceptable strong acid salts... Agent: Tianjin Michele Sci-tech Development Co., Ltd

20110060012 - 4-[3-(aryloxy)benzylidene]-3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors: The present invention relates to compounds of Formula (I), wherein Ar is a 5-membered heteroaryl moiety and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the... Agent: Pfizer Inc.

20110060011 - Oxazole compounds compositions and methods of use: The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.... Agent: Amgen Inc.

20110060013 - Thiazoles and pyrazoles useful as kinase inhibitors: The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the... Agent: Vertex Pharmaceuticals Incorporated

20110060014 - Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents: The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed... Agent:

20110060015 - 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanomethylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists: e

20110060016 - Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient: Disclosed is a method of treatment of COPD by oral administration of roflumilast.... Agent: Nycomed Gmbh

20110060017 - Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetyl-choline receptors. Due to their pharmacological profile, the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent: Neurosearch A/s

20110060018 - Insecticidal n-substituted (2-substituted-1,3-thiazol)alkyl sulfoximines: N-Substituted (2-substituted-1,3-thiazol)alkyl sulfoximines are effective at controlling insects.... Agent:

20110060019 - Heteroaryl-ureas and their use as glucokinase activators: S

20110060020 - Process for release of biologically active species: providing said ordered mesoporous oxide with said fixed or immobilized biologically active species in vivo thereby realizing intraluminally induced substantially pH-independent supersaturation of said biologically active species resulting in enhanced transepithelial transport; wherein said biologically active species is a poorly soluble therapeutic drug classified as belonging to Class II or... Agent: Katholieke Universiteit Leuven K.u. Leuven R&d

20110060021 - Histone deacetylase inhibitors and uses thereof: wherein R1 and R2 are as disclosed herein, and including reduced forms and dehydration products, and salts thereof. Also provided are compositions, including pharmaceutical compositions, methods of inhibiting histone deacetylase, methods of increasing histone deacetylase-controlled gene expression in a cell, methods of treating a disease associated with increased histone deacetylase... Agent:

20110060022 - 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465: 4-[4-(2-Adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid and pharmaceutically-acceptable salts thereof and a particular crystalline form of the Agent (Form 1); their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.... Agent: Astrazeneca Ab

20110060023 - Parasiticidal formulation: The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C1-C6 alcohol co-solvent, wherein the total amount of C1-C6 alcohol is up to 8% by weight of the formulation; at least one organic solvent which is not the C1-C6 alcohol co-solvent; and... Agent:

20110060025 - 3-aminocarbazole compound, pharmaceutical composition containing it and preparation method therefor: The present invention relates to novel benzoyl derivatives of 3-aminocarbazole, to a pharmaceutical composition containing them, to a method for preparing them and to the use of such compounds for the production of a drug that is useful in the treatment or prevention of disturbances associated with the production of... Agent: Aziende Chim. Riun.ang.franc. A.c.r.a.f S.p.a.

20110060024 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20110060026 - Indoles active on crth2 receptor: Indole derivatives having therapeutic utility are of formula (I): X is —SO2— or *—SO2NR3— wherein the bond marked with an asterisk is attached to Ar1; R1 and R2 are, independently, hydrogen, fluoro, chloro, CN or CF3; R3 is hydrogen, C1-C8alkyl or C3-C7cycloalkyl; and Ar1 and Ar2 are, independently, phenyl or... Agent:

20110060036 - Branched multifunctional nanoparticle conjugates and their use: Disclosed herein are compounds and compositions including a polyglycerol nanocarrier, a therapeutic agent or imaging agent, and optionally a targeting agent. In certain aspects the disclosed compounds include biocompatible hyperbranched polymer nanocarriers. Such compounds and compositions are useful for the targeted delivery of antitumor agents and imaging agents to tumors... Agent: Emory University

20110060037 - Use of npy y5 receptor antagonists for the prevention of psycho-stimulant and opioid abuse: The present invention relates to the use of NPY receptor antagonists for the preparation of a medicament for achieving a reduction in and/or prevention of abuse of psycho-stimulants, opioids and related substances.... Agent:

20110060039 - Composition: A cocoa powder having a polyphenol content of at least 5% by weight, may be used to provide skin benefits by oral administration. Preferably, the cocoa powder is provided as part of a foodstuff or confectionary product, or as a cosmetic composition or supplement, The skin benefit preferably comprises a... Agent:

20110060038 - Nitrogenated trans-stilbene analogs, method for the obtention and medical applications thereof: This invention is related to new nitrogenated trans-stilbene compounds, more specifically, imine, pyrrole and indole derivatives, with procedures for the preparation and use thereof as pharmaceutical compositions for the treatment and/or chemoprevention of those mammalian diseases such as cancer, fibrosclerosis and acute/chronic inflammation, graft-versus-host reaction, ischemic-reperfusion tissue injury in stroke... Agent: Universidad Del Pais Vasco

20110060040 - Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid: Methods of using acyloxyalkyl carbamate prodrugs of trans-4-(aminomethyl)-cyclohexanecarboxylic acid and pharmaceutical compositions thereof are disclosed.... Agent: Xenoport, Inc.

20110060042 - External preparation for skin: The present invention provides an external preparation for skin which contains 5-aminolevulinic acids as active components and which is excellent in skin-beautifying effects such as prevention/amelioration of skin roughness, dry skin, wrinkles, sagging and flecks of skin, and improvement of turnover of corneum; and in an ameliorating effect on skin... Agent: Sbi Alapromo Co., Ltd.

20110060041 - Method of reversing, preventing, delaying or stabilizing soft tissue calcification: The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney... Agent:

20110060043 - Inhibitors of cell proliferation and uses thereof: The present invention provides novel compounds that inhibit cell proliferation and uses of these compounds for treating, ameliorating or preventing diseases, conditions or disorders benefiting from the inhibition hyperproliferation.... Agent: European Molecular Biology Laboratory (embl)

20110060044 - Aliphatic acid-containing n-halogenated amino acid formulations: The present invention relates to methods for treating an infected tissue comprising treating the infected tissue with a formulation comprising a N-halogenated amino acid and an aliphatic acid. This specification also discloses methods for improving the antimicrobial activity of a formulation comprising a N-halogenated amino acid, the method comprising adding... Agent: Alcon Research, Ltd.

20110060045 - Anti-diabetic cataract compounds and their uses: R6 represents hydrogen, F, Cl, Br, I, OR10, or SR10, wherein R10 represents hydrogen or an acyl group derived from a linear or branched C1-10 aliphatic acid or a C6-10 aromatic acid, R6 may be present more than once and each R6 may be the same or different, a physiologically... Agent: National Research Council Of Canada

20110060046 - Agent and food for preventing/improving functional digestive disorder: Provided is an agent for the prophylaxis or improvement of functional gastrointestinal disorders, which contains glutamic acid or a salt thereof other than arginine glutamate, and arginine or a salt thereof other than arginine glutamate, as active ingredients. The prophylactic or improvement agent can be produced conveniently and at low... Agent: Ajinomoto Co. Inc.

20110060047 - Approaches to treat cancer using hb-egf inhibitors: The invention provides methods for the treatment of cancer in a subject by the administration of myrsinoic acid A and/or one or more myrsinoic acid A analogs.... Agent: The General Hospital Corporation D/b/a Massachusetts General Hospital

20110060048 - Removing alcohol in vivo through esterification: The present invention is pertaining to a method to chemically remove ethanol in the stomach before a significant amount of ethanol enters the blood stream. The key chemical reaction responsible for ethanol removal is esterification through a reaction between ethanol and acetic acid. Ethanol reacts with acetic acid to produce... Agent:

20110060049 - Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same: This invention concerns N-(2-arylamino) aryl sulfonamide compounds which are inhibitors of MEK including crystalline polymorphic forms which exhibit a specific powder x-ray diffraction profile and/or a specific differential scanning calorimetry profile. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and... Agent: Ardea Biosciences, Inc.

20110060050 - Sgk1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas: The present invention relates to a compound of the formula I, Ia and Ib, and its pharmaceutically usable tautomers, salts, stereoisomers and the enantiomers, including mixtures thereof in all ratios. The present invention furthermore also relates to compounds of the formula II for the prophylaxis and/or treatment of viral diseases... Agent: Merck Patent Gmbh

20110060051 - Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110060052 - Biocidal aldehyde composition for oil and gas extraction: A novel combination of a biocide (Glutaraldehyde or OPA), a surfactant, alcohol, and functional excipients for the oil and gas recovery industry. The surfactant is preferably a dual chain quaternary ammonium compound consisting of a mixture of alkyl dimethy-benzylammonium chlorides and alkyl dimethylethylbenzylammonium, that absorbs onto a surface and alters... Agent:

20110060053 - Crystalline modifications of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol: Crystalline modifications of (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol and mixtures thereof, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of (1R,3R,6R)- or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol.... Agent: Gruenenthal Gmbh

20110060054 - 2-methylene-5-substituted-methylenecyclopentanone derivatives and use thereof: The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder... Agent: Shenyang Pharmaceutical University

20110060059 - Inhibition of the survival of bladder cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of bladder cancer cells and be used as a pharmaceutical composition to inhibit the bladder... Agent: Golden Biotechnology Corporation

20110060056 - Inhibition of the survival of gastric cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of gastric cancer cells and be used as a pharmaceutical composition to inhibit the gastric... Agent: Golden Biotechnology Corporation

20110060055 - Inhibition of the survival of lymphoma by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of lymphoma cells and be used as a pharmaceutical composition to inhibit the lymphoma tumor... Agent: Golden Biotechnology Corporation

20110060058 - Inhibition of the survival of ovarian cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of ovarian cancer cells and be used as a pharmaceutical composition to inhibit the ovarian... Agent: Golden Biotechnology Corporation

20110060057 - Inhibition of the survival of skin cancer by cyclohexenone compounds from antrodia camphorata: The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3 -dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of skin cancer cells and be used as a pharmaceutical composition to inhibit the... Agent: Golden Biotechnology Corporation

20110060060 - Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform: Resveratrol, a stilbenoid antioxidant found in grapes, wine, peanuts and other berries, has been reported to have hypolipidemic properties. Resveratrol and its three analogs (pterostilbene, piceatannol and resveratrol trimethyl ether) were evaluated for their effects on the activation of the peroxisome proliferator-activated receptor alpha (PPARα) isoforms, a receptor shown to... Agent:

  
03/03/2011 > patent applications in patent subcategories. listing by industry category

20110053827 - Intranasal administration: Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region.... Agent:

20110053828 - Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and therapy: The invention relates to a method for infiltration of polypeptides in cells. The invention further relates to the use of the cells and urea-adjuvated polypeptides for the diagnosis, treatment or prevention of diseases. The invention further relates to the detection of polypeptide-specific immune cells.... Agent:

20110053829 - Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule,... Agent:

20110053830 - Methods for treating septic shock: Methods for the treatment of septic shock are disclosed herein. The methods include the use of a therapeutically effective amount of inhibitory peptides that inhibit TLR activity. The peptides can be used with other agents for the treatment of septic shock. In one embodiment, a therapeutically effective amount of a... Agent:

20110053831 - Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.... Agent:

20110053832 - Natural antimicrobial composition: Natural antimicrobials for foods, such as salad dressings and dairy products to target a broad spectrum of food emulsion spoilage microorganisms such as lactic acid bacteria and fungi such as general yeast and even acid-tolerant yeast (such as Zygosaccharomyces bailii). The formulations include at least a combination of a nisin... Agent:

20110053833 - Synthetic peptides and their use: At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars.... Agent:

20110053835 - Antimicrobial peptides derived from cap18: The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The... Agent:

20110053834 - Novel antibiotic peptide derived from ribosomal protein l1 of helicobacter pylori and use thereof: The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of Helicobacter pylori. Specifically, the antibiotic peptide comprising the amino acid sequence of SEQ. ID. NO:1 derived from ribosomal protein L1, RPL1 of Helicobacter pylori is substituted with a... Agent:

20110053836 - Use of defensins against tuberculosis: The present invention relates to a method for killing or inhibiting cells of Mycobacterium, in particular M. tuberculosis, with certain defensins.... Agent:

20110053837 - Mineral-peptide chelates: The present invention provides a mineral-peptide chelate comprising a peptide consisting of 2˜18 amino acids and a mineral chelated to the peptide, wherein the peptide can be a hydrolysate obtained by hydrolyzing soybean or other protein materials with proteases, or a product obtained by hydrolyzing soybean or other protein material... Agent:

20110053839 - Glp-1 derivatives ii: The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.... Agent:

20110053838 - Process for solubilizing glucagon-like peptide 1 compounds: Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution.... Agent:

20110053840 - Allele and isotope-specific intervention on mhc class ii molecules associated with autoimmune diseases by means of peptides: The present invention relates to a peptide for the treatment or prophylaxis of an autoimmune disease, a nucleic acid molecule coding for said peptide, a pharmaceutical composition comprising the peptide and/or the nucleic acid molecule, and to a method for the treatment and/or prophylaxis of an autoimmune disease.... Agent:

20110053841 - N-terminal fgf variants having increased receptor selectivity and uses thereof: The present invention relates to the design, manufacture and use of fibroblast growth factor (FGF) polypeptides having improved receptor specificity. In particular, the invention relates to isolated FGF2 and FGF4 polypeptides that include a truncated N-terminus and optionally N-terminal amino acid substitutions. The present invention provides polypeptides, nucleic acids encoding... Agent:

20110053842 - Targeted therapeutics based on engineered proteins that bind egfr: The present invention relates to single domain proteins that bind to epidermal growth factor receptor (EGFR). The invention also relates to single domain proteins for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to... Agent:

20110053843 - E-selectin compositions and use thereof for inducing e-selectin tolerance: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.... Agent:

20110053844 - Liquid formulation of g-csf conjugate: The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer, the composition having a pH value in the range of 4.5 to 5.5. The composition further comprises a surfactant and optionally one or more other pharmaceutically acceptable excipients. Further, the... Agent:

20110053845 - Localized vaginal delivery without detrimental blood levels: The invention relates to a pharmaceutical composition for vaginal administration of a treating agent normally associated with undesired side effects at detrimental blood levels. The composition releases the treating agent at a rate to achieve local tissue concentrations without such detrimental blood levels by using a therapeutically effective amount of... Agent:

20110053846 - The use of gnrh antagonist peptide in the treatement of sex hormone-dependent diseases: e

20110053847 - Methods of treating vasodilatory shock: The invention encompasses methods of decreasing the lumenal diameter of a blood vessel by contacting the vessel with a myosin light chain phosphatase inhibitor.... Agent:

20110053848 - Prodrug comprising a drug linker conjugate: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the... Agent:

20110053850 - Doc1 compositions and methods for treating cancer: A purified DOC1 polypeptide comprising a fragment of SEQ ID NO: 1 is provided, wherein the DOC1 polypeptide is not the full-length DOC1 polypeptide sequence. A method of inhibiting angiogenesis in a subject is provided comprising administering to a subject a nucleic acid encoding a DOC1 polypeptide, whereby a cell... Agent:

20110053849 - Regulation of litaf modulated cytokine production by a novel p53 short peptide: The present invention relates to a novel isolated and purified peptide of the sequence KQSQHMT [SEQ ID NO: 1], nucleic acid sequences encoding said peptide sequence and capable of expressing said sequence as an exogenous protein in a target cell; as well as methods for the reduction or inhibition of... Agent:

20110053851 - Haemostasis-modulating compositions and uses therefor: This invention discloses the use of snake venom FV polypeptides in methods and compositions for preventing or reducing blood loss or bleeding during bleeding episodes.... Agent:

20110053852 - Use of podocan protein in treating cardiovascular diseases: The present invention relates to compositions and methods for the treatment of intimal smooth muscle cell hyperplasia, restenosis following percutaneous coronary intervention, post-transplant vasculopathy, and pulmonary hypertension More particularly, the present invention relates to methods and pharmaceutical compositions for delivering podocan or podocan inhibitors to the arterial system of an... Agent:

20110053853 - Use of copolymer 1 for treatment of muscular dystrophy: The invention provides an active agent selected from the group consisting of Copolymer 1, a Copolymer 1 related-peptide and a Copolymer 1-related polypeptide, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising the active agent, for use in treating a muscular dystrophy disease or disorder.... Agent:

20110053855 - Ex vivo cell stimulation: Provided herein is are methods for evaluating the biological activity and/or therapeutic potential of a glucan, comprising in one embodiment: co-culturing a first population of cells with a second population of cells, wherein the first population comprises cells capable of being stimulated by said glucan to produce and/or secrete cytokines... Agent:

20110053854 - Treatment of muscular dystrophies and related disorders: The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an... Agent:

20110053856 - Metabolite derivatives of the hdac inhibitor fk228: The present invention relates to HDAC inhibitor derivatives, particularly derivatives of the free thiol of metabolites of the HDAC inhibitor FK228, pharmaceutical compositions thereof, and to methods of using such derivatives and pharmaceutical compositions thereof in the treatment of diseases associated with HDAC, in particular, tumor or cell proliferation diseases.... Agent:

20110053857 - Yeast cells expressing tar dna-binding protein 43 and uses therefor: Disclosed are yeast cells expressing TAR DNA-binding protein 43 (TDP-43) and methods of screening yeast cells to identify compounds that prevent or suppress TDP-43-induced toxicity, compounds that inhibit the formation or maintenance of cytoplasmic inclusions of TDP-43, genetic suppressors or enhancers of TDP-43-induced toxicity, and genetic suppressors or enhancers of... Agent:

20110053858 - Heterocyclic peptide ketoamides: A novel class of peptide α-ketoamides useful for selectively inhibiting calpains, selectively inhibiting cysteine proteases, and generally inhibiting all cysteine proteases, having the formula M-AA2-AA1-CO—NH—(CH2)n—R3. Processes for the synthesis of peptidyl α-ketoamide derivatives. Compositions and methods for inhibiting cysteine proteases, inhibiting calpains, and treating disease caused by cysteine proteases and... Agent:

20110053859 - Methods to reduce the effects of sleep deprivation: The invention provides methods of treating symptoms of sleep deprivation using a hypocretin agonist. The invention also provides methods of treating Parkinson's disease using a hypocretin agonist.... Agent:

20110053860 - Cox-2 function and wound healing: The invention relates to compositions and methods for enhancing bone healing, bone formation and wound healing. More specifically, it relates to the use of cyclooxygenase 2 (COX-2) following bone fracture, orthopaedic procedure or wound infliction to enhance healing.... Agent:

20110053861 - Compositions comprising nuclear factor-kappa b (nf-kb) sirna and methods of use: The present invention provides siRNA nucleic acid molecules that inhibit NF-kappaB expression. Methods of using the nucleic acid molecules are also provided.... Agent:

20110053862 - Compositions comprising survivin sirna and methods of use thereof: The present invention provides siRNA nucleic acid molecules that inhibit survivin expression. Methods of using the nucleic acid molecules are also provided.... Agent:

20110053864 - Compositions and methods for modulation of cell migration: A peptide includes SEQ ID NO:3, substitution and addition variants thereof which maintain the ability to activate CD44. A complex includes this peptide or an Å6 polypeptide with a CD44 polypeptide. An isolated polypeptide includes the Link region sequence of human CD44, functionally active fragments thereof, substitution variants, and addition... Agent:

20110053863 - Methods of using flt3-ligand in the treatment of cancer: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and... Agent:

20110053865 - Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same: The present invention relates to amino acid sequences that are directed against (at defined herein) heterodimeric cytokines and/or their receptors, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consists of one or more such amino acid sequences ( also referred to... Agent:

20110053866 - Pharmaceutical compositions: The present invention provides for a pharmaceutical composition that includes tetrabenazine and a release-retarding agent; and a method of treating a hyperkinetic movement disorder (e.g., Huntington's disease, chorea associated with Huntington's disease, hemiballismus, senile chorea, tic disorders, tardive dyskinesia, myoclonus, dystonia and/or Tourette's syndrome). The method includes administering an effective... Agent:

20110053867 - L-sugar colon cleansing agent and uses thereof: Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.... Agent:

20110053868 - L-sugar colon cleansing agent and uses thereof: Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.... Agent:

20110053869 - Methods and compositions for inhibiting progression to chronic cardiac failure: The present invention is provides methods and formulations for preventing or ameliorating progression to chronic heart failure subsequent to cardiac stress, including as a consequence of myocardial infarction (MI), coronary artery disease, hypertension, cardiomyopathy, myocarditis, valvular regurgitation, severe lung disease, and/or severe anemia of chronic disease, by administration of one... Agent:

20110053871 - Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation: Methods are described for preventing or reducing cytoskeletal rearrangement and intercellular gap formation by contacting cells with an aminoalkyl glucosaminide phosphate. In particular, the disclosed methods can be used to prevent or reduce actin cytoskeletal rearrangement and/or intracellular gap formation related to ischemic or ischemia-reperfusion events and to prevent or... Agent:

20110053870 - Use of isothiocyanate derivatives as anti-myeloma agents: The invention concerns the use of glucomoringin and of its des-thio-glucoside having the following formulae (I, II): for the preparation of a medicament for the treatment of myeloma.... Agent:

20110053873 - Hsp90 inhibitors: The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.... Agent:

20110053872 - Pharmaceutical composition for preventing and treating diabetic nephropathy and the preparation method thereof: The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical... Agent:

20110053874 - Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases: The present invention relates to the use of flavonoid compounds, particularly quercetin-3-O-β-D-glucuronide and kaempferol-3-O-β-D-glucuronide and their glucosides, for preventing diseases of the heart. Red vine leaf extract has proved a particularly advantageous source of the flavonoid compounds in question.... Agent:

20110053875 - Macrolide synthesis process and solid-state forms: This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides.... Agent:

20110053876 - macrolides and their use: The invention relates to macrolide compounds of formula (I), the use of said compounds as medicaments, in particular for the treatment or prevention of inflammatory and allergic diseases, pharmaceutical compositions containing said compounds and to processes for their preparation. The invention relates in particular to macrolide compounds with anti-inflammatory activity... Agent:

20110053877 - Nimesulide and muscle relaxant combinations thereof: A topical pharmaceutical formulation made up of nimesulide or a pharmaceutically acceptable derivative of nimesulide, together with thiocolchicoside or a pharmaceutically acceptable derivative of thiocolchicoside. The present invention more particularly relates to pharmaceutical combinations of nimesulide and thiocolchicoside, in the form of topical gels, ointments, cream, sprays, or lotions with... Agent:

20110053878 - Acid-sensitive linkers for drug delivery: The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.... Agent:

20110053879 - Picoplatin and amrubicin to treat lung cancer: A method for treatment of lung cancer comprising administration of picoplatin and amrubicin, or comprising radiation therapy and picoplatin is provided. A use of picoplatin in conjunction with amrubicin for treatment of lung cancer is provided. The lung cancer can be SCLC or NSCLC. The cancer can be resistant or... Agent:

20110053880 - Composition for treatment of tuberculosis: The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m... Agent:

20110053881 - 6-disubstituted or unsaturated bicyclic nucleic acid analogs: The present disclosure describes 6-disubstituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the 6-disubstituted bicyclic nucleosides each comprise a 2′-O—C(Ri)(R2)-4′ or 2′-O—C=(R3)(R.4)-4′ bridge wherein each R is, independently a substituent group and Ri and R2 include H. The 6-disubstituted bicyclic nucleosides are... Agent:

20110053882 - Methods and compounds for preventing and treating a tumour: The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also... Agent:

20110054003 - Antisense oligonucleotide modulation of stat3 expression: Compounds, compositions and methods are provided for inhibiting the expression of human STAT3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding STAT3. Methods of using these oligonucleotides for inhibition of STAT3 expression and for promotion of apoptosis are provided. Methods for treatment of diseases, particularly inflammatory diseases and... Agent:

20110054007 - Compositions and methods to control insect pests: Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Coleopteran plant pest or a Diabrotica plant pest, decrease the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the... Agent:

20110054004 - Method for reducing scarring during wound healing using antisense compounds directed to ctgf: This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic... Agent:

20110054009 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders: Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed.... Agent:

20110054005 - Polynucleotides for causing rna interference and method for inhibiting gene expression using the same: t

20110054006 - Regulation of oncogenes by micrornas: Naturally occurring miRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA... Agent:

20110054008 - Rnai inhibition of serum amyloid a for treatment of glaucoma: RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.... Agent:

20110054012 - Methods and compositions for increasing gene expression: The present invention provides compositions, pharmaceutical preparations, kits and methods for increasing expression of a gene product in a cell by contacting the cell with a microRNA (miRNA) molecule comprising a ribonucleic strand that is complementary to a non-coding nucleic acid sequence of the gene.... Agent:

20110054011 - Rna antagonist compounds for the modulation of fabp4/ap2: Oligonucleotides directed against the FABP4 gene are developed for modulating the expression of FABP4 protein. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding FABP4. Methods of using these compounds for modulation of FABP4 expression and for the treatment of diseases associated with over expression of FABP4... Agent:

20110054010 - Transcription factor decoys and use thereof: A pharmaceutical composition having a transcription factor decoy and a pharmaceutical acceptable carrier thereof is provided, wherein the transcription factor decoy is TCF decoy. A method for curing or preventing endotoxin-treated endothelial cells from apoptosis is provided. A method for treating or meliorating septic shock is also provided. The transcription... Agent:

20110053883 - Agent that modulates physiological condition of pests, involved in insect c-jun amino-terminal kinase activity: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect c-Jun NH2-terminal kinase; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a c-Jun NH2-terminal... Agent:

20110053884 - Potent combinations of zidovudine and drugs that select for the k65r mutation in the hiv polymerase: Combinations of antiretroviral nucleoside reverse transcriptase inhibitors, and methods for their use in treating retroviral infections, are provided. In one embodiment, the combinations include non-thymidine nucleoside antiretroviral agents, such as tenofovir-DF, abacavir, APD and DAPD, that select for the K65R mutation and relatively low doses of zidovudine (AZT) or other... Agent:

20110053886 - Delayed self-gelling alginate systems and uses thereof: Dispersions that comprise insoluble alginate/gelling ion particles in an alginate solution, wherein the dispersion exhibits less than 10% of final gel storage modulus after one minute in the absence of addition of non-gelling cations are disclosed. Kits and compositions for making such dispersions are disclosed and methods for making and... Agent:

20110053885 - Pharmaceutical agent having long-lasting effect of treating arthritic disorders: The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient... Agent:

20110053887 - Socs3 expression promoter, drug and food containing the same and method of promoting the expression of socs3: A SOCS3 expression promoter includes hyaluronic acid having an average molecular weight of 500,000 or more and/or a salt thereof as an active ingredient.... Agent:

20110053888 - Mixture of carboyhydrates and its use in the preparation of a product intended for oral or enteral nutrition: The present invention is related to a new mixture of carbohydrates and its usage for the preparation of a food product intended for oral or enteral nutrition, particularly for the nutrition of the diabetic patient and in particular for the nutrition of the diabetes type II patient and their associated... Agent:

20110053889 - Prenatal and postnatal screening and treatment of critical monosaccharide deficiencies for neurologic and immunologic function: A method for determining the effect of critical glyconutrient dietary supplements in premature and term infants on growth, health, and brain function during early childhood development is described. The method comprises determining a critical target nutrient profile in typical samples of preterm and mother's milk, developing a supplement of the... Agent:

20110053890 - Synthetic analogs of bacterial quorum sensors: and methods of reducing bacterial pathogenicity, comprising providing a biological system comprising pathogenic bacteria which produce natural quorum-sensing molecule; providing a synthetic bacterial quorum-sensing molecule having the above structures and introducing the synthetic quorum-sensing molecule into the biological system comprising pathogenic bacteria. Further is provided a method of targeted delivery... Agent:

20110053891 - 5-fluoropyrimidinone derivatives: This present disclosure is related to the field of 5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.... Agent:

20110053893 - Compounds and compositions as tlr activity modulators: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 7. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.... Agent:

20110053892 - Imidazo[4,5-d]pyridazine compounds for treating viral infections: Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses:... Agent:

20110053894 - Broad spectrum antiviral and methods of use: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.... Agent:

20110053895 - Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases: The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.... Agent:

20110053896 - Osmolytes for the treatment of allergic or viral respiratory diseases: The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes... Agent:

20110053897 - Compounds and compositions as syk kinase inhibitors: Provided herein area novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated Syk kinase activity.... Agent:

20110053898 - Topical composition comprising vitamin d analogue and corticosteroids: A topical pharmaceutical composition comprising therapeutically effective amounts of vitamin D or vitamin D analogues, corticosteroid and a straight chain C6-C28 fatty alcohol.... Agent:

20110053900 - Progesterone antagonists such as cdb-4124 in the treatment of breast cancer: The subject matter of the instant invention is pertinent to the field of cancer treatment. In particular, the instant invention is relevant to the treatment and/or prevention of breast cancer in a patient. Compositions for practicing the methods, comprising selective progesterone receptor modulators, which function as progesterone agonists in the... Agent:

20110053899 - Use of lanostane and poria extract in treating diabetes: A pharmaceutical composition for treating diabetes is provided in this invention. The composition contains a lanostane compound as a potent component. A suitable source of the lanostane compound is a Poria extract from metabolite, sclerotium, or fermentation product of Poria cocos (Schw) Wolf. The Poria extract contains 1-60% of the... Agent:

20110053901 - Acetyl mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase: Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing... Agent:

20110053902 - Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders: Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the... Agent:

20110053903 - Pharmaceutical compositions based on azetidine derivatives: m

20110053904 - Carbocyclic glyt1 receptor antagonists:

20110053905 - Compounds as tyrosine kinase modulators: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.... Agent:

20110053906 - Protein kinase inhibitors and use thereof: Disclosed are benzonaphthyridinyl derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to kinase signal transduction inhibition, regulation or modulation.... Agent:

20110053907 - Substituted pyrimidines and triazines and their use in cancer therapy: Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine,... Agent:

20110053908 - Azetidine-derived compounds, preparation method therefor and therapeutic use of same: o

20110053909 - Compounds - 801:

20110053910 - 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes:

20110053911 - Tricyclic derivatives as inhibitors of poly(adp-ribose) polymerase (parp): The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative... Agent:

20110053912 - Pyrimidine compound: A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group... Agent:

20110053913 - Methods and therapies for alleviating pain: A method for alleviating or delaying onset of pain in a subject via administration of an ultra low dose of alpha-2 receptor antagonist which does not significantly block or inhibit alpha-2 receptor activity is provided. A non-selective alpha-2 receptor antagonist or a selective alpha-2A receptor antagonist may be administered.... Agent:

20110053914 - Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol or 6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol and an antiepileptic: a medicament comprising such a combination, a kit containing the ingredients of such a combination, and a method of treating pain in which components (a) and (b) are administered simultaneously or sequentially, whereby component (a) may be administered before or after component (b), and in which components (a) and (b)... Agent:

20110053915 - Heterocyclic inhibitors of an hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an hh-signal system: The invention relates to novel heterocyclic compounds and to the use thereof, to pharmaceutical compositions containing said chemical compounds as an active ingredient and to the use thereof for producing medicinal preparations for the human being and warm-blood animals for treating diseases caused by the aberrant activity of an Hedgehog... Agent:

20110053917 - Allosteric modulators of the a1 adenosine receptor: wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the Al adenosine receptor. Accordingly, the compounds of formula... Agent:

20110053916 - Pyrimidine compounds as tuberculosis inhibitors: The present invention relates to compounds useful as inhibitors of treating tuberculosis. The invention also provides processes for preparing compounds of the inventions and... Agent:

20110053918 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or... Agent:

20110053919 - Active compound combinations having insecticidal and acaricidal properties: The novel active compound combinations comprising a compound of the formula (I) or (II) and the active compounds (1) to (6) listed in the description have very good insecticidal and acaricidal properties.... Agent:

20110053920 - Substituted bicyclic pyrimidines: wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula... Agent:

20110053921 - Hexahydrooxazinopterine compounds: e

20110053922 - Spiro (piperidine-4,2'-pyrrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists:

20110053923 - Chemical compounds 610:

20110053925 - Hydroxamate-based inhibitors of deacetylases:

20110053926 - New pharmaceutically-active compounds for the treatment of respiratory diseases:

20110053924 - Substituted piperidines as renin inhibitors: The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which R has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.... Agent:

20110053927 - Nanoparticle formation via rapid precipitation: The invention encompasses a method for making nano-sized particles of water-insoluble pharmaceuticals comprising: (1) dissolving the water-insoluble pharmaceutical in a water-miscible solvent, optionally with water and inactive pharmaceutical ingredients, to make a solution; (2) rapidly mixing the solution with an anti-solvent which creates a high level of supersaturation, wherein the... Agent:

20110053928 - Pyrimidothienoindazoles: The invention relates to novel pyrimidothienoindazoles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.... Agent:

20110053929 - Imidazo-, pyrazolopyrazines and imidazotriazines and their use: The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias.... Agent:

20110053930 - Inhibitors of the bmp signaling pathway: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as... Agent:

20110053932 - Protein kinase inhibitors and methods for using thereof: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or... Agent:

20110053931 - Quinoline compounds and methods of use: Compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof, are useful for inhibiting receptor tyrosine kinases and for treating hyperproliferative disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for... Agent:

20110053933 - Hydroxyquinoxalinecarboxamide derivative: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group;... Agent:

20110053936 - substituted spiro[cycloalkyl-1,3'-indol]-2'(1'h)-one derivatives and their use as p38 mitogen-activated kinase inhibitors: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent:

20110053934 - Compounds and methods of treatment: A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.... Agent:

20110053935 - Fused pyridines active as inhibitors of c-met: Fused pyridines of formula (I) and the pharmaceutically acceptable salts thereof have activity as inhibitors of c-Met and may thus be used to treat various diseases and disorders including cancer. Processes for synthesizing the compounds are also described.... Agent:

20110053937 - Inhibitors of the interaction between mdm2 and p53: s

20110053940 - 3,4-substituted piperidine derivatives as renin inhibitors: The present invention relates to 3,4-substituted piperidinyl-based renin inhibitor compounds bearing at 4-position oxopyridine and having the formula (I). The invention further relates to pharmaceutical compositions containing said compounds, as well as their use in treating cardiovascular events and renal insufficiency.... Agent:

20110053938 - Compounds and compositions for treating cancer: The invention relates to compounds and composition for the treatment and prevention of cancer. The invention also covers all diseases that may be treated by selective modulation of levels of reactive oxygen species in diseased cells versus normal cells. Methods for the preparation and administration of such compositions are also... Agent:

20110053939 - Novel aromatic nitro compounds: Pharmaceutical compositions comprising at least one compound of e.g. the formulas (Ie) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning—X— is e.g. and Y is e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs of the... Agent:

20110053941 - Ido inhibitors: Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an... Agent:

20110053942 - Orally disintegrating tablets: The present invention relates to an orally disintegrating tablet containing (1) an active ingredient, (2) mannitol, (3) crystalline cellulose and (4) at least two kinds of particular ingredients selected from the group consisting of low-substituted hydroxypropylcellulose, cornstarch and carmellose, wherein the blending ratio of each ingredient relative to 100 wt... Agent:

20110053943 - Carbamate and urea inhibitors of 11ß-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the invention pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for... Agent:

20110053946 - Aryl-quinolyl compounds and their use: The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of... Agent:

20110053945 - Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine: Novel mesylate, (R)-mandelate, succinate, citrate, fumarate, D-malate, D-tartrate, sulfate and L-tartrate salts of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) are provided.... Agent:

20110053944 - Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors: Dihydropteridin-6-one derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.... Agent:

20110053947 - Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof: The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.... Agent:

20110053950 - 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors: The present invention relates to compounds of Formula (I) wherein Ar is optionally substituted phenyl or heteroaryl; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases... Agent:

20110053949 - 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors: The present invention relates to compounds of Formula (I), wherein Ar is optionally substituted phenyl or heteroaryl and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing... Agent:

20110053948 - Pyrrolidines as nk3 receptor antagonists: wherein R1, R2, Ar1, Ar2, R′, R″, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease,... Agent:

20110053951 - Methods for treating disorders using nmda nr2b-subtype selective antagonist: A method of treating, preventing or ameliorating a disease or condition by inhibiting NR2B subunit containing NMDA receptors using a compound according to formula (I) or a pharmaceutically acceptable salt thereof:... Agent:

20110053952 - 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors: The invention provides compounds of Formula (I) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such... Agent:

20110053953 - Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compounds and pharmaceutical compositions containing said compounds.... Agent:

20110053954 - Method of treatment and/or prevention of brain, spinal or nerve injury: wherein the meanings of R, R1, R2, R2′, R3, and R4 are explained in the specification and the pharmaceutically acceptable acid addition salts and the prodrugs thereof either alone or in combination with a magnesium salt. Exemplified is the use of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-4-o-tolyl-nicotinamide. The invention also relates to pharmaceutical composition comprising... Agent:

20110053955 - Anti-cytokine heterocyclic compounds: Heterocyclic compounds which are inhibitors of Mitrogen-Activated Protein Kinase-Activated Protein Kinase-2 (MAPKAP-K2) as described, in addition to their use in the treatment of cytokine mediated diseases.... Agent:

20110053956 - Treatment for neurological and mental disorders: Methods for treating neurological or mental disorders in humans and the symptoms associated therewith are provided by administering eltoprazine and/or related compounds. In some embodiments, specific symptoms are treated by administering eltoprazine and/or a related compound in an effective amount to ameliorate the symptoms. Of particular significance are symptoms that... Agent:

20110053957 - Malonate salt of 4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and uses of same: 4-((1R,35)-6-Chloro-3 -phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen malonate salt and pharmaceutical comprising and uses of the same, including for the treatment of schizophrenia and other psychotic disorders are described.... Agent:

20110053958 - Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto: The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated... Agent:

20110053959 - Pyrimidyl cyclopentanes as akt protein kinase inhibitors: The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such... Agent:

20110053960 - Method for treating pain syndrome and other disorders: The present invention provides the use of certain compounds to treat peripheral or central pain syndrome and other disorders associated with the T-type calcium ion channels.... Agent:

20110053961 - Substituted xanthine derivatives: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use... Agent:

20110053962 - Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition: wherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their... Agent:

20110053964 - 4-aminoquinazoline derivatives and methods of use thereof: This invention relates to novel 4-aminoquinazolines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of the EGFR and HER-2.... Agent:

20110053963 - Tartrate salts of quinazoline based egfr inhibitors containing a zinc binding moiety: i

20110053967 - (poly) aminoacetamide derivatives of epipodophyllotoxin their process of preparation and their applications in therapeutics as anticancer agents: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.... Agent:

20110053965 - Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias: This invention relates to pharmaceutical compositions comprising a sulfonated biological precursor of thymidine, such as a precursor of 4-thiothymidine (4-TT), and their use in the photodynamic treatment of skin hyperplasias, including cancer, psoriasis, actinic keratosis and keloids, by topical or systemic administration.... Agent:

20110053966 - Synergistic fungicidal compositions containing a 5-fluoropyrimidine derivative for fungal control in cereals: A fungicidal composition containing a fungicidally effective amount of a) a compound of Formula IA and/or IB and (b) at least one fungicide selected from the group consisting of epoxiconazole, prothioconazole, azoxystrobin, pyraclostrobin, penthiopyrad, isopyrazam, bixafen, boscalid, prochloraz, chlorothalanil, isobutyric acid (3S,6S,7R,8R)-8-benzyl-3-[(3-isobutyryloxymethoxy-4-methoxypyridine-2-carbonyl)-amino]-6-methyl-4,9-dioxo-[1,5]dioxonan-7-yl ester, and (5,8-difluoroquinazolin-4-yl)-{2-[2-fluoro-4-(4-trifluoromethylpyridin-2-yloxy)-phenyl]-ethyl}-amine provides synergistic control of selected... Agent:

20110053968 - Aminopyrimidine inhibitors of tyrosine kinase: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof... Agent:

20110053969 - Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases: The invention provides compounds of general formula. (II) wherein R and are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent:

20110053970 - Spirocyclic cyclohexane compounds useful to treat substance dependency: Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency.... Agent:

20110053971 - Nalmefene di-ester prodrugs: The present invention relates to prodrugs of nalmefene of formula (I), pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of substance abuse disorders such as alcohol abuse and alcohol dependence and impulse control disorders such as pathological gambling and addiction to... Agent:

20110053972 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent:

20110053973 - Compounds as tyrosine kinase modulators: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.... Agent:

20110053974 - Carboxylic acid compound: To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ═C(R5)- or ═N—; Y represents —O— or —NH—; L represents... Agent:

20110053975 - Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one... Agent:

20110053976 - Quinoline derivatives and their use as tyrosine kinase inhibitors: e

20110053977 - Small molecule e2f inhibitor: A small molecular inhibitor of E2F (HLM006474) was identified using a computer-based virtual screen and the known crystal structure of the DNA bound E2F4/DP2 heterodimer. Treatment of multiple cell lines resulted in the loss of intracellular E2F4 DNA-binding activity. Overnight exposure to HLM006474 resulted in down regulation of total E2F4... Agent:

20110053978 - Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter: Therapeutic uses of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine and therapeutically acceptable salts thereof are provided.... Agent:

20110053979 - Pyridine derivatives used to treat orexin related disorders: This invention relates to pyridinamine methyl substituted piperidinyl derivatives I and their use as pharmaceuticals.... Agent:

20110053980 - Indane-amine derivatives, their preparation and use as medicaments: The present invention relates to indane-amine compounds of general formula (I) and compositions thereof, methods for their preparation, and the use of said compounds for the preparation of a medicament for the treatment of humans or animals.... Agent:

20110053981 - Methods and compositions using cholinesterase inhibitors: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic... Agent:

20110053983 - (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity: Embodiments of the invention relate to (5R)-1,5-diaryl-4,5-dihydro-1H-pyrazole-3-carboxamidine derivatives as cannabinoid-CB1 receptor antagonists, to methods for the preparation of these compounds, to novel intermediates useful for the synthesis of said dihydropyrazole derivatives, to methods for the preparation of these intermediates, pharmaceutical compositions containing one or more of these dihydropyrazole derivatives as... Agent:

20110053982 - Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors: The present invention relates to compounds of the Formula (I), and pharmaceutically acceptable salts thereof, and their use in the treatment of FAAH-mediated diseases or condition.... Agent:

20110053984 - Novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel 4-benzhydryloxy-tetraalkyl-piperidine derivatives of Formula (I), any of its stereoisomers or any mixture of its stereoisomers, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein Ra represents hydrogen or C1-6-alkyl; Rb and Rc independent of each other represent a phenyl group, which phenyl group... Agent:

20110053985 - Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: i

20110053986 - Respiratory disease treatment: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the... Agent:

20110053988 - Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke: A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 1.0 mg/ml. The composition used alone assists in reduction of the desire of a subject... Agent:

20110053987 - Pyridinium and thiazolium conjugates including polyethylene glycols and methods of using the same: Pegylated pyridinium and thiazolium compounds and methods of their use in medicine, research, industry, agriculture and recreational activities are disclosed. The present invention also provides methods of controlling microbial growth and infection. Additionally, the present invention provides methods of controlling microbial infestations relating to industrial and agricultural uses. The present... Agent:

20110053989 - Methods and materials for treating orthostatic hypotension or postural tachycardia syndrome: This document provides methods and materials related to treating orthostatic hypotension and/or postural tachycardia syndrome. For example, methods and materials for using a composition containing 3,4-diaminopyridine, 4-aminopyridine, or both to treat patients with orthostatic hypotension, postural tachycardia syndrome, or both orthostatic hypotension and postural tachycardia syndrome are provided.... Agent:

20110053990 - Fatty acid niacin conjugates and their uses: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.... Agent:

20110053992 - Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats): Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.... Agent:

20110053991 - Treatment of histone deacetylase mediated disorders: Provided herein are pharmaceutical agents, pharmaceutical compositions, methods of treatment, treatment regimens and kits for the treatment of histone deacetylase mediated disorders.... Agent:

20110053993 - Prodrugs of desazadesferrothiocin polyether analogues as metal chelation agents: Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of... Agent:

20110053994 - Potent immunosuppressive agents, derivatives and uses: Provided herein include compositions, all related stereoisomers as well as pharmaceutically acceptable salts provided as simplified analogs of pateamine A, in which the analogs generally are devoid of the C3-amino and C5-methyl groups, also referred to as desmethyl, desamino-pateamine A. Suitable analogs provide anticancer and antiproliferative effects in vivo and... Agent:

20110053995 - Benzenesulfonanilide compound inhibitors of urea transporters: Provided herein are small molecule compounds that alter the transport activity of solute transporters, particularly urea transporters. The compounds described herein belong to the benzenesulfonanilide class of compounds. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating cardiovascular, renal, and metabolic... Agent:

20110053996 - Use of phenyltriazoles for controlling insects and spider mites by watering, droplet application or dip application or by treating seed: in which R1, R2 may have the meanings given in the description-, for controlling animal pests such as insects and/or spider mites and/or nematodes by treating the soil/growth substrate by watering, by droplet application, by dip (immersion) application or by treating the seed.... Agent:

20110053997 - salts and crystal forms: The present invention relates to novel salts of the compound (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, polymorphs of the salts and methods of their preparation.... Agent:

20110053998 - Etomidate analogues with improved pharmacokinetic and pharmacodynamic properties: The invention is directed to compounds according to formula (I): where R1 is L1C(O)OT or L1C(O)OL2C(O)OT; R2 is a substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, or C2-C10 alkynyl, or R1; n is an integer from 0 to 5; each R3 is independently halogen or R2; L1 and L2 are... Agent:

20110053999 - 4-methylpyrazole formulations for inhibiting ethanol intolerance: Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent... Agent:

20110054000 - Crystalline modifications of pyraclostrobin: The present invention relates to novel crystalline modifications of pyraclostrobin, to processes for their preparation and to the use of the novel modifications for preparing crop protection compositions.... Agent:

20110054001 - Chk1 suppresses a caspase-2 apoptotic response to dna damage that bypasses p53, bcl-2 and caspase-3: The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and/or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described.... Agent:

20110054002 - Alkyl indole-3-carbinol-derived antitumor agents: e

20110054013 - Tetrahydropyranochromene gamma secretase inhibitors:

20110054014 - Prenylflavanone compounds and uses thereof: The present invention relates to new prenylflavanone compounds and a pharmaceutical composition comprising at least one of the compounds.... Agent:

20110054015 - Solid forms of ortataxel: The present invention relates to solid forms of 13-(N-Boc-β-isobutylserinyl)-14-β-hydroxybaccatin III 1,14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B... Agent:

20110054016 - Method for modulating claudin mediated functions: Disclosed is a method for modulating a claudin-mediated function in a mammalian subject which comprises administering to a subject in need thereof an effective amount of a specific fatty acid derivative. The application also discloses a method for treating a dermatological disease and a method for modulating an expression of... Agent:

20110054017 - Substituted furans and their use: The present application relates to novel substituted furan derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular diseases.... Agent:

20110054018 - Inotilone derivatives as coherent biological response modifier (cbmr): Optimal compositions of derivatives of 5-methyl-3(2H)-furanone compounds and phenylpropanoid polyketides related to inotilone, that exert biological response modification in health and disease, and their method of preparation, are disclosed. Methods of treating degenerative conditions stemming from over-expression of inducible nitric oxide synthase (iNOS) using these compositions are also disclosed.... Agent:

20110054019 - Cancer starvation therapy: The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction... Agent:

20110054020 - Napthylene inhibitors of cyclooxygenase: The present invention relates to new napthylene inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof... Agent:

20110054021 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent:

20110054022 - Method for preparing dicaffeoylquinic acids and use thereof in combating aphids: Method for preparing 3,5-dicaffeoylquinic acid and certain derivatives thereof, and use thereof in the preparation of plant-protection products. Method for combating aphids using 3,5-dicaffeoylquinic acid and certain derivatives thereof.... Agent:

20110054023 - Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a cancer cell, tissue or tumor. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a tumor, increasing sensitivity of a tumor... Agent:

20110054024 - Use of hop acids in fuel ethanol production: Six hop acids are common to hops and beer: alpha acid, beta acids, isoalpha acids, rho-isoalpha acids, tetrahydro-isoalpha acids, and hexahydro-isoalpha acids. The six hop acids were tested to determine which were the most effective in inhibiting the growth of bacteria common to fuel ethanol production. The bacteria used in... Agent:

20110054025 - Use of a pentacyclic triterpene in a pharmaceutical composition for the treatment of multiple sclerosis: Oleanolic acid (3β-hiydroxyolean-12-en-28-oic acid) is a pentacyclic triterpene occurring in a large number of medicinal plants. The present invention is directed to the pharmacological application of the oleanolic acid, alone or in combination with other substances, in the treatment or prophylaxis of neurodegenerative diseases such as multiple sclerosis. The inventors... Agent:

20110054026 - Antimicrobial composition and use: Antimicrobial compositions are provided comprising a pharmaceutically acceptable organic acid and a pharmaceutically acceptable surfactant. This synergistic combination allows compositions to be formulated at low concentrations that have efficacy in reducing bacterial counts by greater than 3 log within 5 minutes of contact while preserving the organoleptic properties of treated... Agent:

20110054027 - Production of biofuel from tissue culture sources: The present invention provides a method for the production of at least one fatty acid and/or oil from a plant cell suspension culture, the method comprising (i) maintaining a cell suspension culture of oil-producing plant cells under conditions such that the cultured cells synthesise and secrete at least one fatty... Agent:

20110054028 - Supplement for reducing hiv transmission and method thereof: There is an urgent need for a method to reduce the risk of mother-to-child transmission (MTCT) of HIV during breastfeeding in HIV pandemic regions. The present invention provides a supplement for reducing the chance of transmitting HIV during MTCT and method thereof. The supplement comprising arachidonic acid (AA) alone, or... Agent:

20110054030 - Use of eicosapentaenoic acid and/or docosahexahenoic acid in women with endometriosis: The present invention pertains to the use of essential fatty acids for the preparation of a food composition for treating in particular post-surgical pain and/or pain due to a post-surgical relapse in women having undergone an operation for endometriosis. Said essential fatty acids are preferably selected from the group consisting... Agent:

20110054029 - Water-soluble dietary fatty acids: Water-soluble dietary fatty acid formulations, solutions, and methods for increasing the water solubility and/or bioavailability of dietary fatty acids, as well as methods for treating various diseases are disclosed.... Agent:

20110054031 - Ophthalmic nsaids as adjuvants: The disclosure provides methods and ophthalmic NSAIDs as adjuvants to VEGF inhibitors useful for treating retinal disorders, including but not limited to wet AMD, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, and branch retinal vein occlusion.... Agent:

20110054032 - Dioxoanthracene sulphonate derivatives: Compounds that may have anti-inflammatory activity have the general formula (I): Wherein R1, R2, R3 are each independently H or a C1-4 alkyl group or a C2-4 acyl group; R4 and R5 are each independently H or a group of formula —SO3R6, wherein R6 is H or a C1-4 alkyl... Agent:

20110054033 - Methods of using abscisic acid for ameliorating hypertension and vascular inflammation: Methods and compositions for treating or preventing hypertension or vascular inflammation are described. These methods of the invention involve the administration of abscisic acid (ABA) to subjects in need thereof.... Agent:

20110054034 - Methods of using carboxylic amides as antimicrobial agents: A method of treating a disease or condition in a warm blooded mammal which disease or condition is suspected to be associated with a microbial infection, comprising: administering an antimicrobial effective amount of a carboxylic acid amide, its isomers or salts thereof, to a subject who is suspected to be... Agent:

20110054035 - Combination comprising combretastatin and anticancer agents: This invention relates to therapeutic combinations comprising VEGF Trap and a stilbene derivative, and to methods for treatment of cancer comprising administration of such combinations.... Agent:

20110054036 - Composition and method for irrigation of a prepared dental root canal: Composition and method for irrigating a prepared dental root canal. The composition is an aqueous composition of ethylenediamine tetraacetic acid, chlorhexidine or orally acceptable addition salt, and N-cetyl-N,N,N-trimethylammonium bromide, and is effective for simultaneous smear layer removal and disinfection.... Agent:

20110054037 - Bis-aromatic anticancer agents: Treatment of cancer includes administering a compound of formula (I) to a subject. In particular, treatment of colorectal cancer is described.... Agent:

20110054038 - Cns pharmaceutical compositions and methods of use: The present invention is directed to CNS pharmaceutical compositions and methods of use. The pharmaceutical compositions comprise a CNS active agent and preferably at least two vagal neuromodulators, one of which is a mechanoreceptor stimulator. The vagal neuromodulators are preferably in an amount sufficient to reduce a somnolence side-effect of... Agent:

20110054039 - Use of alkyl sulfates or sulfonates against propionibacterium acnes: An alkyl sulphate or sulphonate having a carbon chain length of 11 or greater, for use in the treatment of a condition which is caused by, transmitted by and/or exacerbated by propionibacterial activity, in particular acne.... Agent:

20110054040 - Bicyclic triterpenoid iripallidal as a novel anti-glioma and anti-neoplastic therapy: This invention relates to a Bicyclic triterpenoid Iripallidal as a novel anti-glioma and anti neoplastic agent, having the composition [(−)(6R,10S,11S,18R,22S)-26 Hydroxy-22-α methylcyloirid-16-enal NSC 631939], wherein it binds to Ras GRP3, a phorbol ester receptor that links DAG/phorbolester signaling with Ras activation and induces phosphorylation of ER K1/2 in a Ras... Agent:

20110054041 - Oil-in-water type cosmetic emulsion: The invention provides an oil-in-water type cosmetic emulsion which can be applied to the skin without stickiness, and impart resilient and supple feel to the skin, while having good stability without causing viscosity decrease or separation even during a long-term storage. The oil-in-water type cosmetic emulsion comprises (a) a higher... Agent:

20110054043 - Film composition: A film composition comprising (i) a resin obtained by copolymerizing polyvinyl alcohol and at least one or more polymerizable vinyl monomers; and (ii) a drug or a food component.... Agent:

20110054042 - Polymer compositions: A composition contains an incompletely hydrated water soluble polymer suspended in a liquid medium.... Agent:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.77136 seconds

PATENT INFO